Methods and kits for identifying, evaluating, preventing and treating lung diseases

By identifying and measuring the expression levels of specific biomarkers, the problem of difficulty in early diagnosis of non-small cell lung cancer and asthma in the prior art is solved, and early accurate diagnosis and distinction is achieved, and the reliability and sensitivity of diagnosis are improved.

CN113189342BActive Publication Date: 2024-12-03CANCER PREVENTION & CURE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110251315.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2009-08-26
Filing Date
2010-03-12
Publication Date
2024-12-03
Estimated Expiration
2030-03-12

AI Technical Summary

Technical Problem

The prior art lacks a simple and reliable method to diagnose human lung histopathological states in the early stages of the disease, especially non-small cell lung cancer and asthma, and the presence of lung cancer cannot be determined by blood tests, resulting in the diagnosis often occur after the disease progresses.

Method used

By identifying and measuring the expression levels of specific biomarkers, using the Student’s t-test and Kruskal Wallis method to determine significance, a kit is designed to detect these markers to achieve early diagnosis and distinction between non-small cell lung cancer and reactive airway disease .

Benefits of technology

The ability to accurately diagnose and distinguish between non-small cell lung cancer and reactive airway disease in the early stages of the disease is achieved, and the reliability and sensitivity of diagnosis is improved, and the presence of lung cancer and asthma can be predicted through blood tests.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113189342B_ABST
    Figure CN113189342B_ABST
Patent Text Reader

Abstract

The present invention provides biomarkers and combinations of biomarkers for diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The present invention also provides methods for distinguishing lung diseases based on the expression level of biomarkers and combinations of biomarkers, methods for monitoring treatment, and methods for predicting the response of a subject to therapeutic intervention. Kits containing reagents for detecting biomarkers and combinations of biomarkers are also provided.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with international application PCT / US2010 / 027243, international application date March 12, 2010, and Chinese national phase application number 201080017220.5. Background of the Invention

[0003] (a) Field of the Invention

[0004] The present invention relates to the detection, identification, assessment, prevention, diagnosis and treatment of lung diseases using biomarkers and kits thereof. More specifically, the present invention relates to the diagnosis of non-small cell carcinoma and reactive airway disease by measuring and quantifying the expression levels of specific markers. The present invention also relates to the identification of biomarkers present in human serum or other biological fluids, which, when found to be expressed at levels different from those found in a normal population, are indicative of pathologies associated with human lung tissue and the human respiratory system. By identifying markers associated with these pathologies, quantifying the expression levels of these biomarkers, and comparing the expression levels with the levels normally expected to be present in normal human serum, it is possible to detect the presence of pathologies early in their progression and to characterize the progression of said pathologies, as well as to differentiate between pathologies, through a simple blood test.

[0005] (b) Description of Related Art

[0006] Respiratory conditions, such as asthma and lung cancer, affect millions of Americans. In fact, the American Lung Association ) reports that almost 20 million Americans suffer from asthma. According to the American Cancer Society, there were 229,400 new cases of respiratory cancer and 164,840 deaths from respiratory cancer in 2007 alone. Although the five-year survival rate for all cancer cases when the cancer is detected while it is still localized is 46%, the five-year survival rate for lung cancer patients is only 13%. Correspondingly, only 16% of cancers are discovered before the disease spreads. Lung cancer is usually classified into two main types based on the pathological state of the cancer cells. Each type is named according to the type of cell that transforms into cancer. Small cell lung cancer originates from small cells in human lung tissue, while non-small cell lung cancer generally includes all lung cancers that are not small cell types. Because the treatment for all non-small cell types is usually the same, non-small cell lung cancers are grouped together. Overall, non-small cell lung cancer, or NSCLC, accounts for about 75% of all lung cancers.

[0007] One of the main factors for the low survival rate of lung cancer patients is based on the fact that lung cancer is difficult to diagnose in its early stages. Current methods of diagnosing lung cancer or identifying its presence in humans are limited to performing X-rays, computed tomography (CT) scans, and similar lung tests to physically determine the presence or absence of a tumor. Therefore, lung cancer diagnosis is often only made in response to symptoms that have been present for a significant period of time, and only after the disease has been present in a person long enough to produce a physically detectable mass.

[0008] Similarly, current methods of detecting asthma are generally performed after symptoms such as recurrent wheezing, coughing, and chest tightness have been present for a long time. Current methods of detecting asthma are generally limited to lung function tests such as spirometry tests or challenge tests. In addition, physicians often require these tests along with a variety of other tests to rule out other pathological conditions or reactive airway diseases such as chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and congestive heart failure.

[0009] There does not exist in the art a simple and reliable method for diagnosing a human lung tissue pathology early in its development. Further, there is no blood test available today that can detect the presence of a specific lung tissue pathology. Therefore, there is a need to develop a method to determine the presence of lung cancer early in the progression of the disease. Similarly, there is a need to develop a method to diagnose asthma and non-small cell lung cancer at the earliest onset of symptoms, as well as to distinguish them from each other and from other lung diseases such as infection. There is a further need to identify specific proteins present in human blood that, when altered in relative expression intensity, indicate the presence of non-small cell lung cancer and / or reactive airway disease. SUMMARY OF THE INVENTION

[0011] The present invention has identified a number of biomarkers that can be used to characterize the physiological state of a subject with respect to a lung disease such as non-small cell lung cancer or reactive airway disease. These biomarkers are shown in Tables 1-23.

[0012] Table 1A lists biomarkers whose expression levels when measured in individuals with one or more lung diseases are found to be different from the levels in normal individuals. Table 1B lists biomarkers whose expression levels when measured in individuals with non-small cell lung cancer or reactive airway disease are found to be different from the levels in normal individuals, and which are found to show differential expression levels between non-small cell lung cancer and reactive airway disease. Table 1C lists biomarkers whose expression in individuals with non-small cell lung cancer or reactive airway disease is found to be different from the levels in normal individuals when measured.

[0013] Table 2 lists biomarkers whose expression has been found to differ from levels in normal individuals when measured in individuals with reactive airway disease. Table 3 lists biomarkers whose expression has been found to differ from levels in normal individuals when measured in individuals with non-small cell lung cancer. Table 4 lists biomarkers whose expression levels have been found to differ between individuals with non-small cell lung cancer and reactive airway disease when measured.

[0014] Table 5A lists biomarkers whose expression levels have been found to be different from the levels in normal males when measured in males with one or more lung diseases. Table 5B lists biomarkers whose expression levels have been found to be different from the levels in normal males when measured in males with non-small cell lung cancer or reactive airway disease, and which have been found to show differential expression levels between non-small cell lung cancer and reactive airway disease. Table 5C lists biomarkers whose expression has been found to be different from the levels in normal males when measured in males with non-small cell lung cancer and reactive airway disease.

[0015] Table 6 lists biomarkers whose expression has been found to differ from the levels in normal males when measured in males with reactive airway disease. Table 7 lists biomarkers whose expression levels have been found to differ from the levels in normal males when measured in males with non-small cell lung cancer. Table 8 lists biomarkers whose expression levels have been found to differ when measured between males with non-small cell lung cancer and reactive airway disease.

[0016] Table 9A lists biomarkers whose expression levels have been found to be different from the levels in normal women when measured in women with one or more lung diseases. Table 9B lists biomarkers whose expression levels have been found to be different from the levels in normal women when measured in women with non-small cell lung cancer or reactive airway disease, and which have been found to show differential expression levels between non-small cell lung cancer and reactive airway disease. Table 9C lists biomarkers whose expression has been found to be different from the levels in normal women when measured in women with non-small cell lung cancer and reactive airway disease.

[0017] Table 10 lists biomarkers whose expression has been found to differ from levels in normal women when measured in women with reactive airway disease. Table 11 lists biomarkers whose expression has been found to differ from levels in normal women when measured in women with non-small cell lung cancer. Table 12 lists biomarkers whose expression levels have been found to differ between women with non-small cell lung cancer or reactive airway disease when measured.

[0018] Table 13A lists biomarkers whose expression differed significantly between male and female reactive airway disease populations. Table 13B lists biomarkers whose expression did not differ significantly between male and female reactive airway disease populations. Table 14A lists biomarkers whose expression differed significantly between male and female non-small cell lung cancer populations. Table 14B lists biomarkers whose expression did not differ significantly between male and female non-small cell lung cancer populations. Table 15A lists biomarkers sorted by relative standard deviation of fluorescence intensity in normal populations. Table 15B lists biomarkers sorted by relative standard deviation of fluorescence intensity in normal female populations. Table 15C lists biomarkers sorted by relative standard deviation of fluorescence intensity in normal male populations.

[0019] Table 16A lists biomarkers whose expression levels have been found to be different from the levels in normal males when measured in males with one or more lung diseases. Table 16B lists biomarkers whose expression levels have been found to be different from the levels in normal males when measured in males with non-small cell lung cancer or reactive airway disease, and which have been found to show differential expression levels between non-small cell lung cancer and reactive airway disease. Table 16C lists biomarkers whose expression has been found to be different from the levels in normal males when measured in males with non-small cell lung cancer and reactive airway disease.

[0020] Table 17 lists biomarkers whose expression has been found to differ from the levels in normal males when measured in males with reactive airway disease. Table 18 lists biomarkers whose expression has been found to differ from the levels in normal males when measured in males with non-small cell lung cancer. Table 19 lists biomarkers whose expression levels have been found to differ between males with non-small cell lung cancer and reactive airway disease when measured.

[0021] Table 20A lists biomarkers whose expression levels have been found to be different from the levels in normal women when measured in women with one or more lung diseases. Table 20B lists biomarkers whose expression levels have been found to be different from the levels in normal women when measured in women with non-small cell lung cancer or reactive airway disease, and which have been found to show differential expression levels between non-small cell lung cancer and reactive airway disease. Table 20C lists biomarkers whose expression has been found to be different from the levels in normal women when measured in women with non-small cell lung cancer and reactive airway disease.

[0022] Table 21 lists biomarkers whose expression has been found to differ from the levels in normal women when measured in women with reactive airway disease. Table 22 lists biomarkers whose expression has been found to differ from the levels in normal women when measured in women with non-small cell lung cancer. Table 23 lists biomarkers whose expression levels have been found to differ between women with non-small cell lung cancer or reactive airway disease when measured.

[0023] The significance of Tables 1-15 was determined using Student's t test. The significance of Tables 16-23 was determined using the Kruskal Wallis method.

[0024] Polypeptides comprising SEQ ID NOs: 1-17 are additional biomarkers whose expression has been found to be altered in accordance with one or more lung diseases.

[0025] The present invention provides a variety of diagnostic, prognostic and therapeutic methods that rely on the identification of these biomarkers.

[0026] The present invention provides a method for performing physiological characterization in a subject, comprising determining the expression level of at least one biomarker from any number in Tables 1-12 or 16-23 in a physiological sample of the subject, wherein the expression level of the at least one biomarker indicates a lung disease such as non-small cell lung cancer or reactive airway disease, or assists in distinguishing a lung disease such as non-small cell lung cancer or reactive airway disease. The present invention also provides a method for performing physiological characterization in a subject, comprising determining the expression level of at least one biomarker from Tables 13B, 14B or 15B and also appearing on Tables 1-12 or 16-23 in a physiological sample of the subject, preferably the biomarker is at least one of the biomarkers No. 1-10 in Tables 1-12 or 16-23, wherein the expression level of the at least one biomarker indicates a lung disease such as non-small cell lung cancer or reactive airway disease. Alternatively, or in addition, the expression level of the first-order interactors of these biomarkers can be determined.

[0027] The present invention provides a method for performing physiological characterization in a subject, comprising determining the expression level of SEQ ID NO: 12 in a physiological sample of the subject, wherein the expression level of SEQ ID NO: 12 indicates a lung disease such as non-small cell lung cancer or reactive airway disease.

[0028] The present invention provides a method for performing physiological characterization in a subject, comprising determining the expression level of at least one polypeptide selected from SEQ ID NO: 1-17 in a physiological sample of the subject, and determining the expression level of at least one biomarker from any number in Table 1-12 or 16-23, wherein the at least one polypeptide and the at least one biomarker from any number in Table 1-12 or 16-23 indicate a lung disease such as non-small cell lung cancer or reactive airway disease.

[0029] The present invention provides a method for diagnosing reactive airway disease in a subject, comprising determining the expression level of at least one biomarker from Table 2, Table 6, Table 10, Table 17 and Table 21 in a physiological sample of the subject, wherein the expression level of the at least one biomarker is indicative of reactive airway disease.

[0030] The present invention provides a method for diagnosing non-small cell lung cancer in a subject, comprising determining the expression level of at least one biomarker from Table 3, Table 7, Table 11, Table 18 or Table 22 in a physiological sample of the subject, wherein the expression level of the at least one biomarker is indicative of non-small cell lung cancer.

[0031] The present invention provides a diagnostic method for assisting in distinguishing the likelihood that a subject has a risk of developing non-small cell lung cancer or reactive airway disease, comprising determining the expression level of at least one biomarker from Table 4, Table 8, Table 12, Table 19 or Table 23 in a physiological sample of a subject having at least one risk of non-small cell lung cancer or reactive airway disease, wherein the expression level of at least one biomarker from Table 4, Table 8, Table 12, Table 19 or Table 23 assists in distinguishing the likelihood that the subject has a risk of developing non-small cell lung cancer or reactive airway disease.

[0032] The present invention provides a method for predicting the likelihood that a patient will respond to a therapeutic intervention, comprising determining the level of expression of at least one biomarker described herein in a physiological sample of the subject, wherein the level of expression of the at least one biomarker assists in predicting the subject's response to the therapeutic intervention.

[0033] The present invention also provides a method for monitoring a subject, comprising determining a first expression level of at least one biomarker described herein in a physiological sample of the subject, determining a second expression level of the at least one biomarker in the physiological sample of the subject at a subsequent time to the first determination, and comparing the first expression level to the second expression level.

[0034] The present invention also provides a method of designing a kit, comprising selecting at least one biomarker described herein, selecting means for determining the expression level of the at least one biomarker, and designing a kit comprising the means for determining the expression level.

[0035] The present invention also provides a method for designing a kit, comprising selecting at least one biomarker described herein, selecting a detection reagent for detecting the at least one biomarker, and designing a kit comprising the detection reagent for detecting the at least one biomarker.

[0036] The invention also provides kits comprising at least one biomarker described herein.

[0037] The present invention also provides a kit comprising means for determining the expression level of at least one polypeptide selected from SEQ ID NO:12.

[0038] The present invention also provides a kit comprising a detection reagent for detecting at least one polypeptide selected from SEQ ID NO:12.

[0039] The present invention also provides a kit comprising (a) a means for determining the expression level of at least one polypeptide selected from SEQ ID NOs: 1-17, and (b) a means for determining the expression level of at least one biomarker from any one of Tables 1-12 or Tables 16-23.

[0040] The present invention also provides a kit comprising (a) a detection reagent for detecting at least one polypeptide selected from SEQ ID NOs: 1-17, and (b) a detection reagent for detecting at least one biomarker from any one of Tables 1-12 or 16-23.

[0041] The present invention further provides kits containing biomarkers and / or polypeptides from the above tables. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1A The mean fluorescence intensity levels of the biomarkers in the normal (NO) population from Example 1 are shown, along with the standard deviation and relative standard deviation.

[0044] Figure 1B The mean fluorescence intensity levels of the biomarkers in the non-small cell lung cancer (LC) population from Example 1 are shown, along with the standard deviation and relative standard deviation.

[0045] Figure 1C The mean fluorescence intensity levels of the biomarkers in the asthma (AST) population from Example 1 are shown, along with the standard deviation and relative standard deviation.

[0046] Figure 1D The percent change in the mean value of the fluorescence intensity of each biomarker from Example 1 for the LC population versus the NO population, the AST population versus the NO population, and the LC population versus the AST population is shown.

[0047] Figure 1E The probabilities associated with Student's t values ​​obtained by comparing the mean fluorescence intensity and variance measured for each biomarker in the populations from Example 1 are shown, where the populations to be compared are the LC population versus the NO population, the AST population versus the NO population, and the LC population versus the AST population, respectively.

[0048] Figure 2A The mean fluorescence intensity levels of the biomarkers in the normal (NO) population from Example 2 are shown, along with the standard deviation and relative standard deviation.

[0049] Figure 2B The mean fluorescence intensity levels of the biomarkers in the non-small cell lung cancer (LC) population from Example 2 are shown, along with the standard deviation and relative standard deviation.

[0050] Figure 2C The mean fluorescence intensity levels of the biomarkers in the asthma (AST) population from Example 2 are shown, along with the standard deviation and relative standard deviation.

[0051] Figure 2D The percent change in the mean value of the fluorescence intensity of each biomarker from Example 2 for the LC population versus the NO population, the AST population versus the NO population, and the AST versus the LC population is shown.

[0052] Figure 2E The probabilities associated with Student's t values ​​obtained by comparing the mean fluorescence intensity and variance measured for each biomarker in the populations from Example 2 are shown, where the populations to be compared are the LC population versus the NO population, the AST population versus the NO population, and the AST population versus the LC population, respectively.

[0053] Figure 3A The mean fluorescence intensity levels of the biomarkers in the normal (NO) population from Example 3 are shown, along with the standard deviation and relative standard deviation.

[0054] Figure 3B The mean fluorescence intensity levels of the biomarkers in the non-small cell lung cancer (LC) population from Example 3 are shown, along with the standard deviation and relative standard deviation.

[0055] Figure 3C The mean fluorescence intensity levels of the biomarkers in the asthma (AST) population from Example 3 are shown, along with the standard deviation and relative standard deviation.

[0056] Figure 3D The percent change in the mean value of the fluorescence intensity of each biomarker from Example 3 for the AST population versus the NO population, the LC population versus the NO population, and the AST population versus the LC population is shown.

[0057] Figure 3E The probabilities associated with Student's t values ​​obtained by comparing the mean fluorescence intensity and variance measured for each biomarker in the populations from Example 3 are shown, where the populations to be compared are AST population versus NO population, LC population versus NO population, and AST versus LC population, respectively.

[0058] Figure 4A The mean fluorescence intensity levels of the biomarkers in the normal (NO) female population from Example 3 are shown, along with the standard deviation and relative standard deviation.

[0059] Figure 4B The mean fluorescence intensity levels of the biomarkers in the female population with non-small cell lung cancer (LC) from Example 3 are shown, along with the standard deviation and relative standard deviation.

[0060] Figure 4C The mean fluorescence intensity levels of the biomarkers in the female population with asthma (AST) from Example 3 are shown, along with the standard deviation and relative standard deviation.

[0061] Figure 4D The percent change in the mean value of the fluorescence intensity of each biomarker from Example 3 for the AST population versus the NO female population, the LC population versus the NO female population, and the AST population versus the LC female population is shown.

[0062] Figure 4E The probabilities associated with Student's t values ​​obtained by comparing the mean fluorescence intensity and variance measured for each biomarker in the populations from Example 3 are shown, wherein the populations to be compared are the AST population versus the NO female population, the LC population versus the NO female population, and the AST population versus the LC female population, respectively.

[0063] Figure 5A The mean fluorescence intensity levels of the biomarkers in the normal (NO) male population from Example 3 are shown, along with the standard deviation and relative standard deviation.

[0064] Figure 5B The mean fluorescence intensity levels of the biomarkers in the male population with non-small cell lung cancer (LC) from Example 3 are shown, along with the standard deviation and relative standard deviation.

[0065] Figure 5CThe mean fluorescence intensity levels of the biomarkers in the asthma (AST) male population from Example 3 are shown, along with the standard deviation and relative standard deviation.

[0066] Figure 5D The percent change in the mean value of the fluorescence intensity of each biomarker from Example 3 for the AST population versus the NO male population, the LC population versus the NO male population, and the AST population versus the LC male population is shown.

[0067] Figure 5E The probabilities associated with Student's t values ​​obtained by comparing the mean fluorescence intensity and variance measured for each biomarker in the populations from Example 3 are shown, where the populations to be compared are the AST versus NO male population, the LC versus NO male population, and the LC versus AST male population, respectively.

[0068] Fig. 6A The percent change in the mean fluorescence intensity of each biomarker from Example 3 for the AST male population compared to the AST female population, the LC male population compared to the LC female population, and the NO male population compared to the NO female population is shown.

[0069] Figure 6B The probabilities associated with Student's t values ​​obtained by comparing the mean fluorescence intensity and differences measured for each biomarker in the male and female populations from Example 3 are shown, where the populations to be compared are the AST male and female population, the LC male and female population, and the NO male and female population, respectively.

[0070] Fig. 7A The percent change in mean concentration of each biomarker for the LC vs. NO female population, the AST vs. NO female population, and the AST vs. LC female population from Example 3 is shown.

[0071] Figure 7B The probability of association calculated by the Kruskal Wallis test comparing the concentrations measured for each biomarker for the female populations from Example 3 is shown, wherein the populations to be compared are the AST vs. NO female population, the LC vs. NO female population, and the AST vs. LC female population, respectively.

[0072] Fig. 8A The percent change in mean concentration of each biomarker for the LC vs. NO male population, the AST vs. NO male population, and the AST vs. LC male population from Example 3 is shown.

[0073] Figure 8BThe probability of association calculated by the Kruskal Wallis test comparing the concentrations measured for each biomarker for the male populations from Example 3 is shown, wherein the populations to be compared are the AST vs. NO male population, the LC vs. NO male population, and the AST vs. LC male population, respectively.

[0074] Fig. 9 The relationships among the biomarkers of Table 16B are shown. DETAILED DESCRIPTION OF THE INVENTION

[0076] The present invention relates to a variety of methods for detecting, identifying, evaluating, preventing, diagnosing and treating lung diseases using biomarkers, including detection, identification, evaluation, prevention, diagnosis and treatment of diseases based on gender. These methods involve determining the expression level of specific biomarkers, whose altered expression indicates non-small cell lung cancer and / or reactive airway disease (e.g., asthma, chronic obstructive pulmonary disease, etc.). The present invention also provides a variety of kits, which contain test reagents for detecting these biomarkers or tools for determining the expression level of these biomarkers.

[0077] As used herein, a "biomarker" or "marker" is a biological molecule that is objectively measured as a characteristic indicator of the physiological state of a biological system. For the purposes of this disclosure, biological molecules include ions, small molecules, peptides, proteins, and peptides and proteins with post-translational modifications, nucleosides, nucleotides and polynucleotides including RNA and DNA, glycoproteins, lipoproteins, and various covalent or non-covalent modifications of these types of molecules. Biological molecules include any class of these entities that are intrinsic, characteristic, and / or critical to the function of a biological system. The majority of biomarkers are polypeptides, although they may also be pre-translational forms of mRNA or modified mRNA representing a gene product expressed as a polypeptide, or they may include post-translational modifications of the polypeptide.

[0078] As used herein, "subject" refers to any animal, but preferably a mammal, such as a human. In many embodiments, the subject is a human patient who has a lung disease or is at risk of developing a lung disease.

[0079] As used herein, "physiological samples" include samples from biological fluids and tissues. Biological fluids include whole blood, plasma, serum, sputum, urine, sweat, lymph and bronchoalveolar lavage fluid. Tissue samples include biopsies from solid lung tissue or other solid tissues, lymph node biopsies, metastatic biopsies. Methods for obtaining physiological samples are well known.

[0080] As used herein, "therapeutic intervention" includes the administration of one or more therapeutic agents such as small or large molecules, radiation, surgery, or a combination thereof.

[0081] As used herein, "detection reagents" include reagents and systems that specifically detect the biomarkers described herein. Detection reagents include reagents such as antibodies, nucleic acid probes, aptamers, lectins, or other reagents that have a specific affinity for a specific marker or markers sufficient to distinguish the specific markers from other markers that may be present in a target sample, as well as systems such as sensors, including sensors that utilize bound or immobilized ligands as described above.

[0082] Identification of biomarkers

[0083] The biomarkers of the present invention were identified using two methods. First, biomarkers indicative of non-small cell lung cancer and / or asthma were identified by comparing the expression levels of 59 selected biomarkers measured in the plasma of patients from a population that had been diagnosed with the respective pathological state with those from a population that had not been diagnosed with the pathological state (confirmed by a physician). This method is described in detail in Examples 1-3.

[0084] The second is to identify biomarkers using mass spectrometry. The mass spectrometry data obtained from the digestion of tryptic peptides from samples of patients with different physiological states are compared to identify proteins indicating non-small cell lung cancer and / or asthma. Specifically, the data is the mass of peptide fragments, which is a graphical display of the intensity of false or protonated molecular ion signals of peptides and proteins containing these fragments expressed over a period of time in a single dimension. Comparing the expression levels of thousands of proteins, 17 proteins were identified, which had great differences in expression intensity between the groups of individuals with lung tissue pathology without any diagnosis, the groups of individuals with asthma (diagnosed by physicians) and the groups of individuals with non-small cell lung cancer (diagnosed by physicians). This method is described in detail in Examples 6 and 7.

[0085] First order interactors

[0086] To promote and control the various physiological functions of cells and organs necessary to maintain life, biological molecules must interact with each other. These interactions can be considered a type of communication. In this communication, various biological molecules are considered to be information. As an essential part of their signal transduction function, these molecules must interact with a wide range of targets including other types of biological molecules.

[0087] One type of interacting molecule is generally referred to as a receptor. Another type of direct intermolecular interaction is the binding of a cofactor to an enzyme. These intermolecular interactions form a network of signaling molecules that work together to perform and control key life functions of cells and organs. The specific biomarkers of the present invention are physiologically linked to other biomarkers, and their levels increase or decrease in a manner that is synergistic with the levels of the specific biomarkers. These other biomarkers are referred to as "first order interactors" relative to the specific biomarkers of the present invention.

[0088] "First-order interactors" are those molecular entities that interact directly with specific biological molecules. For example, the drug morphine directly interacts with opiate receptors and ultimately leads to pain elimination. Therefore, under the definition of "first-order interactors", opiate receptors are first-order interactors. First-order interactors include the direct neighbors of the biomarkers in the upstream and downstream of their interactive communication pathways. These entities include proteins, nucleic acids, and small molecules that can be connected by different relationships, including but not limited to direct (or indirect) regulation, expression, chemical reaction, molecular synthesis, binding, promoter binding, protein modification, and molecular transport. The group of biomarkers that are coordinated horizontally is well known to those skilled in the art and physiologists and cell biologists. In fact, the first-order interactors for specific biomarkers are known in the art and can be found using a variety of databases and available bioinformatics software such as ARIADNE PATHWAY STUDIO, ExPASY Proteomics Server Qlucore Omics Explorer, Protein Prospector, PQuad, ChEMBL, and others. (See, e.g., ARIADNE PATHWAY STUDIO, Ariadne, Inc.,<www.ariadne.genomics.com> or ChEMBL Database,EuropeanBioinformatics Institute,European Molecular Biology Laboratory,<www.ebi.ac.uk> ).

[0089] When the level of a specific biomarker of the present invention is abnormal, the level of a first order interactor biomarker whose expression is synergistic with the specific biomarker is also abnormal. Therefore, determining that the level of a specific biomarker is abnormal can be accomplished by measuring the level of the first order interactor that is expected to be synergistic. The skilled person will naturally confirm that the level of the first order interactor used in place of or in addition to a specific biomarker will vary in a determined, reproducible manner consistent with the behavior of the specific biomarker.

[0090] The present invention provides the following methods for any of the methods described herein, and the method to be performed with a specific biomarker can alternatively be performed with the first order interactors of that specific biomarker. For example, the present invention provides a physiological qualitative method comprising determining the expression level of HGF. Thus, the present invention also provides a physiological qualitative method comprising determining the expression level of the first order interactors of HGF. The first order interactors of HGF include, but are not limited to, those identified in Example 12.

[0091] Identification of significant biomarkers

[0092] Table 1A lists biomarkers whose expression levels are significantly or marginally significantly different between at least one of the AST vs. NO population, the LC vs. NO population, and the AST vs. LC population. As shown in Examples 1-3, significance was determined using a Student's t-test. Markers are listed in descending order based on the significance and magnitude of the difference in fluorescence intensity.

[0093]

[0094]

[0095] Table 1B lists biomarkers whose expression levels are significantly different between the AST relative NO population, LC relative NO population, and AST relative LC population. As shown in Examples 1-3, significance was determined using a Student's t test. Marginally significant biomarkers were not included. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0096]

[0097]

[0098] Table 1C lists biomarkers whose expression levels are significantly or marginally significantly different between the AST vs. NO population and the LC vs. NO population. As shown in Examples 1-3, significance was determined using a Student's t-test. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0099]

[0100] Table 2 lists biomarkers whose expression levels were significantly or marginally significantly different between AST vs. NO groups. Significance was determined using the Student's t-test as shown in Examples 1-3. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0101]

[0102]

[0103] Table 3 lists biomarkers whose expression levels were significantly or marginally significantly different between the LC vs. NO populations. Significance was determined using the Student's t-test as shown in Examples 1-3. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0104]

[0105]

[0106] Table 4 lists biomarkers whose expression levels were significantly or marginally significantly different between AST and LC populations. As shown in Examples 1-3, significance was determined using the Student's t-test. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0107]

[0108] Table 5A lists biomarkers whose expression levels are significantly or marginally significantly different between at least one of the AST vs. NO male population, the LC vs. NO male population, and the AST vs. LC male population. As shown in Examples 1-3, significance was determined using a Student's t test. Markers are listed in descending order based on the significance and magnitude of the difference in fluorescence intensity.

[0109]

[0110] Table 5B lists biomarkers whose expression levels are significantly different between the AST vs. NO male population, the LC vs. NO male population, and the AST vs. LC male population. As shown in Examples 1-3, significance was determined using a Student's t test. Marginally significant biomarkers were not included. Markers were listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0111]

[0112] Table 5C lists biomarkers whose expression levels are significantly or marginally significantly different between the AST vs. NO male population, and the LC vs. NO male population. As shown in Examples 1-3, significance was determined using the Student's t-test. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0113]

[0114]

[0115] Table 6 lists biomarkers whose expression levels were significantly or marginally significantly different between the AST vs. NO male groups. Significance was determined using the Student's t-test as shown in Examples 1-3. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0116]

[0117] Table 7 lists biomarkers whose expression levels were significantly or marginally significantly different between the LC vs. NO male groups. Significance was determined using the Student's t-test as shown in Examples 1-3. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0118]

[0119] Table 8 lists biomarkers whose expression levels were significantly or marginally significantly different between the AST vs. LC male populations. As shown in Examples 1-3, significance was determined using the Student's t-test. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0120]

[0121]

[0122] Table 9A lists biomarkers whose expression levels differ significantly or marginally between at least one of the AST vs. NO female population, the LC vs. NO female population, and the AST vs. LC female population. As shown in Examples 1-3, significance was determined using a Student's t-test. Markers are listed in descending order based on the significance and magnitude of the difference in fluorescence intensity.

[0123]

[0124]

[0125] Table 9B lists biomarkers whose expression levels are significantly different between the AST vs. NO female population, the LC vs. NO female population, and the AST vs. LC female population. As shown in Examples 1-3, significance was determined using a Student's t test. Marginally significant biomarkers were not included. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0126]

[0127] Table 9C lists biomarkers whose expression levels were significantly or marginally significantly different between the AST vs. NO female population and the LC vs. NO female population. As shown in Examples 1-3, significance was determined using a Student's t-test. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0128]

[0129]

[0130] Table 10 lists expression levels that were significantly or marginally significantly different between the AST vs. NO female groups. Significance was determined using a Student's t-test as shown in Examples 1-3. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0131]

[0132]

[0133] Table 11 lists biomarkers whose expression levels differed significantly or marginally between the LC vs. NO female groups. Significance was determined using the Student's t-test as shown in Examples 1-3. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0134]

[0135] Table 12 lists biomarkers whose expression levels were significantly or marginally significantly different between the AST vs. LC female populations. As shown in Examples 1-3, significance was determined using the Student's t-test. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0136]

[0137]

[0138] Table 13A lists biomarkers whose expression levels differed significantly or marginally between male and female AST populations. As shown in Examples 1-3, significance was determined using a Student's t-test. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0139]

[0140] Table 13B lists biomarkers whose expression levels were not significantly different between male and female AST populations. As shown in Examples 1-3, significance was determined using a Student's t-test. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0141]

[0142]

[0143] Table 14A lists biomarkers whose expression levels differed significantly or marginally between male and female LC populations. Significance was determined using a Student's t-test as shown in Examples 1-3. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0144]

[0145]

[0146] Table 14B lists biomarkers whose expression levels were not significantly different between male and female LC populations. As shown in Examples 1-3, significance was determined using a Student's t-test. Markers are listed in descending order based on the significance and magnitude of the difference in fluorescence intensity.

[0147]

[0148] Table 15A lists the following biomarkers, sorted in descending order of relative standard deviation of fluorescence intensity of the normal population.

[0149]

[0150] Table 15B lists the following biomarkers, sorted in descending order of relative standard deviation of fluorescence intensity in a normal female population.

[0151]

[0152]

[0153] Table 15C lists the following biomarkers, sorted in descending order of relative standard deviation of fluorescence intensity in a normal male population.

[0154]

[0155]

[0156] Table 16A lists biomarkers whose expression levels differ significantly between at least one of the AST vs. NO male population, the LC vs. NO male population, and the AST vs. LC male population. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers were listed in descending order based on the significance and magnitude of the difference in fluorescence intensity.

[0157]

[0158]

[0159] Table 16B lists biomarkers whose expression levels were significantly different between the AST vs. NO male population, the LC vs. NO male population, and the AST vs. LC male population. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers were listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0160]

[0161] Table 16C lists biomarkers whose expression levels differed significantly between the AST vs. NO male population and the LC vs. NO male population. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers were listed in descending order based on the significance and magnitude of the difference in fluorescence intensity.

[0162]

[0163] Table 17 lists biomarkers whose expression levels differed significantly between the AST vs. NO male groups. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0164]

[0165]

[0166] Table 18 lists biomarkers whose expression levels differed significantly between the LC vs. NO male groups. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0167]

[0168] Table 19 lists biomarkers whose expression levels differed significantly between the AST vs. LC male populations. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0169]

[0170] Table 20A lists biomarkers whose expression levels differed significantly between at least one of the AST vs. NO female population, the LC vs. NO female population, and the AST vs. LC female population. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers were listed in descending order based on the significance and magnitude of the difference in fluorescence intensity.

[0171]

[0172]

[0173] Table 20B lists biomarkers whose expression levels were significantly different between the AST vs. NO female population, the LC vs. NO female population, and the AST vs. LC female population. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers were listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0174]

[0175] Table 20C lists biomarkers whose expression levels were significantly different between the AST vs. NO female population and the LC vs. NO female population. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0176]

[0177]

[0178] Table 21 lists biomarkers whose expression levels differed significantly between the AST vs. NO female groups. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0179]

[0180] Table 22 lists biomarkers whose expression levels differed significantly between the LC vs. NO female groups. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0181]

[0182] Table 23 lists biomarkers whose expression levels differed significantly between the AST vs. LC female populations. Significance was determined using the Kruskal Wallis method as shown in Example 4. Marginally significant biomarkers were not included. Markers are listed in descending order based on the magnitude of the difference in fluorescence intensity.

[0183]

[0184]

[0185] Determine the level of expression

[0186] The degree of expression generally relates to the quantitative measurement of the expression product (generally a protein or polypeptide). The present invention includes determining the degree of expression of RNA (before translation) or protein levels (which may include post-translational modifications). Specifically, the present invention includes determining changes in biomarker concentrations, which are reflected in increases or decreases in the levels of transcription, translation, post-translational modifications, or in the degree or degree of protein degradation, wherein these changes are associated with specific disease states or disease progression.

[0187] Samples are collected to ensure that the degree of expression in the subject is proportional to the concentration of the biomarker in the sample. Measurements are made so that the measured value is proportional to the concentration of the biomarker in the sample. Thus, the measured value is proportional to the degree of expression. It is within the skill of the art to select sampling and measurement techniques that are appropriate to these requirements.

[0188] Generally, the degree of expression of at least one biomarker indicative of lung disease is a level of at least one biomarker that differs to a statistically significant degree from the average expression level in normal individuals; in other words, at least one biomarker is statistically deviated from normal. Statistical significance and deviation can be determined using any known method for comparing population means or comparing measurements and means of populations. These methods include performing a Student's t-test on single or multiple markers considered together, performing analysis of variance (ANOVA), and the like.

[0189] As an alternative or combined way to determine the degree of expression, the methods described herein include determining whether the level of a biomarker is within a normal level (e.g., range) or exceeds a normal level (i.e., abnormal). Those who measure the level of biological molecules in physiological samples routinely determine the normal level of a specific biomarker in a population that they routinely measure, which is generally described as a normal range of values ​​determined by a specific laboratory. Therefore, the technician will inevitably be familiar with the normal level of a specific biomarker and can determine whether the biomarker level exceeds a normal level or range.

[0190] More generally, the degree of expression of at least one biomarker indicative of a lung disease is a level of at least one biomarker that is sufficiently different in magnitude to be analytically significant from the average expression level in normal individuals, such that a diagnosis, prediction, and / or assessment of the lung disease can be determined. Those skilled in the art will appreciate that greater differences in magnitude are preferred in aiding in the diagnosis, prediction, and / or assessment of lung disease. See Instrumental Methods of Analysis, Seventh Edition, 1988.

[0191] Many proteins expressed by normal subjects will be expressed to a greater or lesser extent in subjects with a disease or condition, such as non-small cell lung cancer or asthma. It will be clear to those skilled in the art that most diseases exhibit changes in multiple, different biomarkers. In this way, a disease can be characterized by the expression pattern of multiple markers. In fact, the expression pattern of multiple biomarkers can be used for a variety of diagnostic and predictive methods, as well as monitoring, treatment selection and patient assessment methods. The present invention provides these methods. These methods include determining the expression pattern of multiple markers for a specific physiological state, or determining changes in such a pattern that are associated with changes in physiological state, which are characterized by any technology used for suitable pattern recognition.

[0192] Numerous methods for determining the extent of expression are known in the art. Methods for determining expression include, but are not limited to, radio-immunoassay, enzyme-linked immunosorbent assay (ELISA), high pressure liquid chromatography using radiometric or spectrometric detection via visible or ultraviolet light absorption, qualitative and quantitative analysis by mass spectrometry, western blot, 1 or 2-dimensional gel electrophoresis (which is quantitatively visualized by means of radioactive, fluorescent or chemiluminescent probes or nuclei), antibody-based absorption or fluorescence photometric detection, luminescence quantification of any of a number of chemiluminescent reporter systems, enzyme assays, immunoprecipitation or immunocapture assays, solid and liquid phase immunoassays, protein arrays or chips, DNA arrays or chips, plate assays, assays using molecules with binding affinity (which allow for the distinction of, for example, aptamers and molecular imprinted polymers), and any other quantitative analysis of biomarker concentrations by any other suitable technique, any of the described detection techniques or instruments used.

[0193] The step of determining the extent of expression may be performed by any means known in the art for determining expression, in particular those discussed herein. In a preferred embodiment, the step of determining the extent of expression comprises performing an immunoassay with an antibody.

[0194] Selecting biomarkers for assay

[0195] Those skilled in the art can easily select appropriate antibodies for use in the present invention. The selected antibodies are preferably selective for the target antigen, have high binding specificity for the antigen, and have minimal cross-reactivity with other antigens. The ability of the antibody to bind to the target antigen can be determined, for example, by known methods such as enzyme-linked immunosorbent assay (ELISA), flow cytometry and immunohistochemistry. Preferably, the target antigen bound by the antibody is differentially present in cells or biological samples taken from diseased patients relative to cells or biological samples taken from healthy patients. The differential presence of antigens in different populations can be determined by comparing the binding of antibodies to samples taken from various target populations (e.g., diseased populations relative to healthy populations). See, for example, Examples 1-4; see also Figures 1-8. For example, it can be determined that the target antigen is expressed at a higher level in cancer cells than in non-cancerous cells. See, for example, Examples 1-4; see also Figures 1-8. Further, the antibody should have a relatively high binding specificity for the target antigen. The binding specificity of the antibody can be determined by known methods such as immunoprecipitation or by in vitro binding assays such as radioimmunoassay (RIA) or ELISA. Disclosure of methods for selecting antibodies capable of binding to an antigen of interest with high binding specificity and minimal cross-reactivity is provided in, for example, US Pat. No. 7,288,249, which is hereby incorporated by reference in its entirety.

[0196] The present invention provides a variety of methods, comprising the step of measuring the expression of one or more biomarkers described herein. In one embodiment, the method includes measuring the expression of any biomarker from any number in Tables 1-14 or 16-23. The biomarkers in Tables 1-14 and 16-23 are generally listed in descending order of expression. Biomarkers close to the top of these tables show higher sensitivity (e.g., differences are detected at lower levels). Using these biomarkers can assist in distinguishing disease conditions. The biomarkers in Table 15 are listed in descending order based on the relative standard deviation of fluorescence intensity. Due to the lower variance caused by the presence of disease states rather than variance, biomarkers close to the top of Table 15 are also generally more sensitive. Specifically, these biomarkers have less overall variability, and therefore help to reduce background noise when comparing the expression of sick individuals with the expression of normal individuals.

[0197] Thus, a preferred method comprises determining the expression level of biomarkers No. 1-20 (or all listed biomarkers when the table contains less than 20) in a specific table. Alternatively, this mode comprises determining the expression level of biomarkers No. 1-10, more preferably biomarkers No. 1-8, even more preferably biomarkers No. 1-6, most preferably biomarkers No. 1-4, or a subset of biomarkers in any of these groups. In another embodiment, the method comprises determining the expression level of any combination of biomarkers from a specific table. In another embodiment, the method includes determining the expression level of the following markers: any combination of multiple biomarkers from biomarkers No. 1-20 (or the most listed biomarkers when there are less than 20) in a specific table, preferably any combination of multiple biomarkers from biomarkers No. 1-10, more preferably any combination of multiple biomarkers from biomarkers No. 1-8, even more preferably any combination of biomarkers from biomarkers No. 1-6, most preferably any combination of multiple biomarkers from biomarkers No. 1-4, or a subgroup of biomarkers in any of these groups. In a preferred mode, the method includes determining the expression level of any specific subgroup of three biomarkers selected from biomarkers No. 1-6, 1-8, 1-10, 1-15 or 1-20 in a specific table. Alternatively, the method includes determining the expression level of any specific subgroup of 4, 5, 6 or 7 biomarkers selected from biomarkers No. 1-8, 1-10, 1-15 or 1-20 in a specific table. Alternatively, the method comprises determining the expression level of any specific subset of 8, 9, 10, 11, 12 or 13 biomarkers selected from biomarkers No. 1-15 or 1-20 in a specific table. Of course, the skilled person will recognize that it is within the scope of the present invention to simultaneously determine the expression level of other biomarkers, whether related to the target disease or not.

[0198] The determination of the expression level of multiple biomarkers prompts people to observe the change pattern of expression, which provides a more sensitive and more accurate diagnosis than detecting individual biomarkers. For example, the change pattern may include a variety of specific biomarkers expressed simultaneously at abnormal levels. The change pattern may also include abnormal increases in some specific biomarkers while abnormal reductions in other specific biomarkers. The technician will observe these patterns in the data presented in the accompanying drawings included herein (see discussion in Example 4 below). This determination can be performed in a composite or matrix-based form such as a composite immunoassay.

[0199] In another embodiment, the method comprises determining the expression level of any biomarker from at least two tables (e.g., Table 2 and Table 3). In another embodiment, the method comprises determining the expression level of biomarkers No. 1-20 of a specific table (or the most listed biomarkers when less than 20) and biomarkers No. 1-20 from a different table (or the most listed biomarkers when less than 20), preferably biomarkers No. 1-10 from one or both tables, more preferably biomarkers No. 1-8 from one or both tables, even more preferably biomarkers No. 1-6 from one or both tables, most preferably biomarkers No. 1-4 from one or both tables, or a subset of biomarkers in any of these groups. In another embodiment, the method comprises determining the expression level of any combination of multiple biomarkers from a specific table and a different table. In another embodiment, the method comprises determining the degree of expression of any combination of multiple biomarkers from biomarkers No. 1-20 (or the most listed biomarkers when less than 20) of a particular table and any combination of multiple biomarkers from biomarkers No. 1-20 (or the most listed biomarkers when less than 20) of a different table, preferably any combination of multiple biomarkers from biomarkers No. 1-10 of one or both tables, more preferably any combination of multiple biomarkers from biomarkers No. 1-8 of one or both tables, even more preferably any combination of multiple biomarkers from biomarkers No. 1-6 of one or both tables, most preferably any combination of multiple biomarkers from biomarkers No. 1-4 of one or both tables, or a subset of biomarkers of any of these groups. In another embodiment, the multiple biomarkers from one table are not present in any other table. In a preferred mode, the method comprises determining the expression level of any specific subset of three biomarkers selected from biomarkers No. 1-6, 1-8, 1-10, 1-15 or 1-20 of a specific table and any specific subset of three biomarkers selected from biomarkers No. 1-6, 1-8, 1-10, 1-15 or 1-20 of another table. Alternatively, the method comprises determining the expression level of any specific subset of 4, 5, 6 or 7 biomarkers selected from biomarkers No. 1-8, 1-10, 1-15 or 1-20 of a specific table and any specific subset of 4, 5, 6 or 7 biomarkers selected from biomarkers No. 1-8, 1-10, 1-15 or 1-20 of another table.Alternatively, the method comprises determining the expression level of any specific subset of 8, 9, 10, 11, 12 or 13 biomarkers selected from biomarkers No. 1-15 or 1-20 of a specific table and any specific subset of 8, 9, 10, 11, 12 or 13 biomarkers selected from biomarkers No. 1-15 or 1-20 of another table. Of course, the skilled artisan will recognize that it is within the scope of the present invention to simultaneously determine the expression level of other biomarkers, whether related or unrelated to the disease of interest.

[0200] It will be appreciated that the same type of combination may be applied when the method comprises determining the extent of expression of any biomarker from at least three different tables (e.g., Table 2, Table 3, and Table 4). For example, in one embodiment, the method comprises determining the extent of expression of any combination of multiple biomarkers from biomarkers No. 1-20 (or the most listed biomarkers when less than 20) of the first table, any combination of multiple biomarkers from biomarkers No. 1-20 (or the most listed biomarkers when less than 20) of the second table, and any combination of multiple biomarkers from biomarkers No. 1-20 (or the most listed biomarkers when less than 20) of the third table, preferably any combination of multiple biomarkers from biomarkers No. 1-10 of each table, more preferably any combination of multiple biomarkers from biomarkers No. 1-8 of each table, even more preferably any combination of multiple biomarkers from biomarkers No. 1-6 of each table, and most preferably any combination of multiple biomarkers from biomarkers No. 1-4 of each table. In a preferred mode, the method includes determining the expression level of any specific subset of three biomarkers selected from biomarkers No. 1-6, 1-8, 1-10, 1-15 or 1-20 of the first table, any specific subset of three biomarkers selected from biomarkers No. 1-6, 1-8, 1-10, 1-15 or 1-20 of the second table, and any specific subset of three biomarkers selected from biomarkers No. 1-6, 1-8, 1-10, 1-15 or 1-20 of the third table. Alternatively, the method includes determining the expression level of any specific subset of 4, 5, 6 or 7 biomarkers selected from biomarkers 1-8, 1-10, 1-15 or 1-20 of the first table, any specific subset of 4, 5, 6 or 7 biomarkers selected from biomarkers 1-8, 1-10, 1-15 or 1-20 of the second table, and any specific subset of 4, 5, 6 or 7 biomarkers selected from biomarkers 1-8, 1-10, 1-15 or 1-20 of the third table. Alternatively, the method comprises determining the expression level of any specific subset of 8, 9, 10, 11, 12 or 13 biomarkers selected from biomarkers No. 1-15 or 1-20 of the first table, any specific subset of 8, 9, 10, 11, 12 or 13 biomarkers selected from biomarkers No. 1-15 or 1-20 of the second table, and any specific subset of 8, 9, 10, 11, 12 or 13 biomarkers selected from biomarkers No. 1-15 or 1-20 of the third table. Of course, the skilled artisan will recognize that it is within the scope of the present invention to simultaneously determine the expression level of other biomarkers, whether related or unrelated to the disease of interest.

[0201] The measurement of the expression levels of multiple biomarkers allows observation of patterns of expression changes, which provide a more sensitive and accurate diagnosis than the measurement of individual biomarkers. Such measurements can be performed in a multiplex or matrix-based format such as a multiplex immunoassay.

[0202] In other embodiments, the extent of expression of no more than 5, 10, 15, 20, 25, 30, 35, or 40 markers is determined.

[0203] The use of known relationships between specific biomarkers and their first order interactors can facilitate the selection of biomarkers for diagnostic or predictive assays. Many, if not all, of the biomarkers identified by the inventors (see Tables 1-23) participate in a variety of communication pathways in cells or organs. Deviations from normal in one component of a communication pathway are expected to be accompanied by associated deviations in other members of the communication pathway. A skilled worker can readily link members of a communication pathway using a variety of databases and available bioinformatics software (see, e.g., ARIADNE PATHWAY STUDIO, Ariadne, Inc.,<www.ariadne.genomics.com> or ChEMBL Database,European BioinformaticsInstitute,European Molecular Biology Laboratory,<www.ebi.ac.uk> ). Diagnostic methods are likely to maximize the information gathered by measuring biomarker levels, wherein the diagnostic methods are based on determining whether a plurality of biomarkers are abnormal, wherein the plurality of biomarkers includes some biomarkers that are not in the same communication pathway as other markers in the plurality of biomarkers.

[0204] It is also to be understood that the various biomarker combinations discussed above may also be applied to the methods of designing kits and kits described herein.

[0205] It will be appreciated that the selection criteria discussed above, including selection preferences for particular subsets of markers, may be employed in any of the methods described herein with reference to those tables associated with the particular method.

[0206] Physiological qualitative

[0207] The present invention is directed to the method for the qualitative physiology of individual in multiple groups as described below. As used herein, the qualitative physiology method according to the method of the present invention includes the method for diagnosing specific diseases, the method for predicting the possibility of individual response to therapeutic intervention, the method for monitoring individual response to therapeutic intervention, the method for determining whether an individual has individual disease risk, the method for determining the risk degree for a specific disease, the method for grading the severity of the disease of the patient and the method for distinguishing the disease with some identical symptoms. Generally, these methods depend on the expression degree of the specific biomarker determined as described above.

[0208] A. General Group

[0209] The present invention provides methods for physiological characterization in a subject. In one embodiment, the present invention provides a method for physiological characterization in a subject, comprising determining the expression level of at least one biomarker from Table 1A in a physiological sample of the subject, wherein the expression level of the at least one biomarker indicates a lung disease such as reactive airway disease or non-small cell lung cancer, or assists in distinguishing reactive airway disease from non-small cell lung cancer. In another embodiment, the method comprises determining the expression level of at least one biomarker from Table 1B, wherein the expression level of the at least one biomarker indicates reactive airway disease or non-small cell lung cancer, or assists in distinguishing reactive airway disease from non-small cell lung cancer. In another embodiment, the method comprises determining the expression level of at least one biomarker from Table 1C, wherein the expression level of the at least one biomarker indicates reactive airway disease or non-small cell lung cancer.

[0210] In another embodiment, the method comprises determining the level of expression of SEQ ID NO: 12. In another embodiment, the method comprises determining the level of expression of SEQ ID NO: 12 and any one of SEQ ID NOs: 1-11 and 13-17.

[0211] In a preferred embodiment, the present invention provides a method for performing physiological qualitative analysis in a subject, comprising determining the expression level of multiple biomarkers from Table 1A in a physiological sample of the subject, wherein the expression pattern of the multiple markers is associated with a change in a physiological state or condition, or a disease state (e.g., the stage of non-small cell lung cancer) or condition. In another preferred embodiment, the expression pattern of multiple biomarkers from Table 1A indicates a lung disease such as non-small cell lung cancer or reactive airway disease, or assists in distinguishing reactive airway disease or non-small cell lung cancer. Preferably, the multiple biomarkers are selected based on a low probability of incorrect pattern classification (based on the student t value calculated in the embodiment). In another preferred embodiment, the expression pattern of the biomarkers from Table 1A is associated with an increased likelihood that the subject suffers from or may suffer from a specific disease or condition. In a more preferred embodiment, the method for determining the expression level of multiple biomarkers from Table 1A detects an increased likelihood that the subject is developing, suffering from, or may suffer from a lung disease such as non-small cell lung cancer or reactive airway disease (e.g., asthma). The expression pattern can be qualitatively characterized by any technique known in the field of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 1A.

[0212] The present invention also provides a method for performing physiological characterization in a subject, comprising determining the expression level of SEQ ID NO: 12 in a physiological sample of the subject, wherein the expression level of SEQ ID NO: 12 indicates a lung disease such as reactive airway disease or non-small cell lung cancer. In a preferred embodiment, the expression pattern of multiple markers of SEQ ID NO: 12 and any one of SEQ ID NOs: 1-11 and 13-17 is determined and used as described herein.

[0213] In another aspect, the invention provides a method for performing physiological characterization in a subject, comprising (a) obtaining a physiological sample from the subject; (b) determining the level of expression of at least one polypeptide selected from SEQ ID NOs: 1-17 in the subject, and (c) determining the level of expression of at least one biomarker from Table 1A in the subject, wherein the levels of expression of the polypeptide and the biomarker from Table 1A are both indicative of a lung disease of non-small cell lung cancer or reactive airway disease. In another embodiment, the expression patterns of multiple markers of SEQ ID NOs: 1-17 and multiple biomarkers from Table 1A are determined and used as described herein.

[0214] In one embodiment, the subject has a risk of lung disease of non-small cell lung cancer or reactive airway disease (e.g., asthma, chronic obstructive pulmonary disease, etc.). "At-risk" subjects include those who are asymptomatic but are more likely to develop the disease than most people due to personal or family history, behavior, exposure to disease-inducing agents (e.g., carcinogens) or some other reasons. "At-risk" individuals are routinely identified by gathering risk factors determined for the individual. The present invention provides enhanced detection of "at-risk" individuals by determining the expression level of relevant biomarkers. In one embodiment, the level of specific biomarkers (specifically, biomarkers from Table 2 or Table 3) associated with the disease is determined for the individual, and the level that is different from the expected level of all normal populations indicates that this individual is "at-risk". In another embodiment, the number of relevant biomarkers (from Table 2 or Table 3, applicable to the disease) that are statistically deviated from normal is determined, and a larger number of deviation markers indicates a greater risk.

[0215] The embodiments described above refer to the biomarkers of Table 1A. However, it is to be understood that the biomarkers of Table 1B or 1C may be substituted for the biomarkers of Table 1A in any of the embodiments described. It is also to be understood that the various biomarkers to be assayed in these specific methods may be selected from the identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Assay".

[0216] B. Male group

[0217] The present invention provides a method for performing physiological characterization in a male subject. In one embodiment, the present invention provides a method for performing physiological characterization in a male subject, comprising obtaining a sample from the male subject, and determining the expression level of at least one biomarker from Table 5A or 16A in the physiological sample of the male subject, wherein the expression level of the at least one biomarker indicates a lung disease such as reactive airway disease or non-small cell lung cancer, or assists in distinguishing reactive airway disease from non-small cell lung cancer. In another embodiment, the method comprises determining the expression level of at least one biomarker from Table 5B or 16B, wherein the expression level of the at least one biomarker indicates reactive airway disease or non-small cell lung cancer, or assists in distinguishing reactive airway disease from non-small cell lung cancer. In another embodiment, the method comprises determining the expression level of at least one biomarker from Table 5C or 16C, wherein the expression level of the at least one biomarker indicates reactive airway disease or non-small cell lung cancer.

[0218] In a preferred embodiment, the present invention provides a method for physiological qualitative analysis in male subjects, comprising determining the expression of multiple biomarkers from Table 5A or 16A in a physiological sample of a male subject, wherein the expression pattern of the multiple markers is associated with a change in a physiological state or condition, or a disease state (e.g., the stage of non-small cell lung cancer) or condition. In another preferred embodiment, the expression pattern of multiple biomarkers from Table 5A or 16A indicates a lung disease such as non-small cell lung cancer or reactive airway disease, or assists in distinguishing reactive airway disease or non-small cell lung cancer. Preferably, the multiple biomarkers are selected based on a low probability of incorrect pattern classification (based on the student t value calculated in the embodiment). In another preferred embodiment, the expression pattern of the biomarkers from Table 5A or 16A is associated with an increased likelihood that a male subject suffers from or may suffer from a specific disease or condition. In a more preferred embodiment, the method for determining the expression of multiple biomarkers from Table 5A or 16A detects that a male subject is developing, suffering from, or may suffer from a lung disease such as non-small cell lung cancer or reactive airway disease (e.g., asthma) and has an increased likelihood. The expression pattern may be characterized by any technique known in the art of pattern recognition technology.The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 5A or 16A.

[0219] In another aspect, the present invention provides a method for performing physiological characterization in a male subject, comprising (a) obtaining a physiological sample from a male subject; (b) determining the expression level of at least one polypeptide selected from SEQ ID NOs: 1-17 in the subject, and (c) determining the expression level of at least one biomarker from Table 5A or 16A in the subject, wherein the expression levels of the polypeptide and the biomarker from Table 5A or 16A are both indicative of a lung disease of non-small cell lung cancer or reactive airway disease. In another embodiment, the expression levels of multiple markers of SEQ ID NOs: 1-17 and multiple biomarkers from Table 5A or 16A are determined and used as described herein.

[0220] In one embodiment, male subjects have the risk of lung disease of non-small cell lung cancer or reactive airway disease (e.g., asthma, chronic obstructive pulmonary disease, etc.). "At risk" subjects and individuals have been discussed above. In one embodiment, the level of specific biomarkers (specifically, biomarkers from Tables 6, 7, 17 or 18) associated with the disease is determined for male individuals, and the level that is different from the expected level of the normal population indicates that this male individual is "at risk". In another embodiment, the number of relevant biomarkers (from Tables 6, 7, 17 or 18, applicable to the disease) that are statistically deviated from normal is determined, and a larger number of deviation markers indicates a greater risk.

[0221] The embodiments described above refer to the biomarkers of Table 5A or 16A. However, it is to be understood that in any of the embodiments described, the biomarkers of Table 5B or 5C can be substituted for the biomarkers of Table 5A, and the biomarkers of Table 16B or 16C can be substituted for the biomarkers of Table 16A. It is also to be understood that the various biomarkers to be assayed in these specific methods can be selected from the identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Assaying".

[0222] C. Female groups

[0223] The present invention provides a method for performing physiological characterization in a female subject. In one embodiment, the present invention provides a method for performing physiological characterization in a female subject, comprising obtaining a sample from the female subject, and determining the expression level of at least one biomarker from Table 9A or 20A in the physiological sample of the female subject, wherein the expression level of the at least one biomarker indicates a lung disease such as reactive airway disease or non-small cell lung cancer, or assists in distinguishing reactive airway disease from non-small cell lung cancer. In another embodiment, the method comprises determining the expression level of at least one biomarker from Table 9B or 20B, wherein the expression level of the at least one biomarker indicates reactive airway disease or non-small cell lung cancer, or assists in distinguishing reactive airway disease from non-small cell lung cancer. In another embodiment, the method comprises determining the expression level of at least one biomarker from Table 9C or 20C, wherein the expression level of the at least one biomarker indicates reactive airway disease or non-small cell lung cancer.

[0224] In a preferred embodiment, the present invention provides a method for physiological qualitative analysis in female subjects, comprising determining the expression level of multiple biomarkers from Table 9A or 20A in a physiological sample of a female subject, wherein the expression pattern of the multiple markers is associated with a change in a physiological state or condition, or a disease state (e.g., the stage of non-small cell lung cancer) or condition. In another preferred embodiment, the expression pattern of multiple biomarkers from Table 9A or 20A indicates a lung disease such as non-small cell lung cancer or reactive airway disease, or assists in distinguishing reactive airway disease or non-small cell lung cancer. Preferably, the multiple biomarkers are selected based on a low probability of incorrect pattern classification (based on the student's t value calculated as in the embodiment). In another preferred embodiment, the expression pattern of multiple biomarkers from Table 9A or 20A is associated with an increased likelihood that a female subject suffers from or may suffer from a specific disease or condition. In a more preferred embodiment, the method for determining the expression level of multiple biomarkers from Table 9A or 20A detects that a female subject is developing, suffering from, or may suffer from a lung disease such as non-small cell lung cancer or reactive airway disease (e.g., asthma) and has an increased likelihood. The expression pattern may be characterized by any technique known in the art of pattern recognition technology.The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 9A or 20A.

[0225] In another aspect, the present invention provides a method for performing physiological characterization in a female subject, comprising (a) obtaining a physiological sample from a female subject; (b) determining the level of expression of at least one polypeptide selected from SEQ ID NOs: 1-17 in the subject, and (c) determining the level of expression of at least one biomarker from Table 9A or 20A in the subject, wherein the level of expression of the polypeptide and the biomarker from Table 9A or 20A are both indicative of a lung disease of non-small cell lung cancer or reactive airway disease. In another embodiment, the expression patterns of multiple markers of SEQ ID NOs: 1-17 and multiple biomarkers from Table 9A or 20A are determined and used as described herein.

[0226] In one embodiment, female subjects have the risk of lung disease of non-small cell lung cancer or reactive airway disease (e.g., asthma, chronic obstructive pulmonary disease, etc.). "At risk" subjects and individuals have been discussed above. In one embodiment, the level of specific biomarkers (specifically, biomarkers from Tables 10, 11, 21 or 22) associated with the disease is determined for female individuals, and the level that is different from the expected level of the normal population indicates that this female individual is "at risk". In another embodiment, the number of relevant biomarkers (from Tables 10, 11, 21 or 22, applicable to the disease) that are statistically deviated from normal is determined, and a larger number of deviation markers indicates a greater risk.

[0227] The embodiments described above refer to the biomarkers of Table 9A or 20A. However, it is to be understood that in any of the embodiments described, the biomarkers of Table 9B or 9C can be substituted for the biomarkers of Table 9A, and the biomarkers of Table 20B or 20C can be substituted for the biomarkers of Table 9A. It is also to be understood that the various biomarkers to be assayed in these specific methods can be selected from the identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Assay".

[0228] Lung disease

[0229] The present invention provides a variety of diagnostic and predictive methods for lung diseases. Specifically, the present invention provides methods for diagnosing reactive airway diseases, specifically diseases associated with overly reactive TH2 and TH17 cells. Reactive airway diseases include asthma, chronic obstructive pulmonary disease, allergic rhinitis, cystic fibrosis, bronchitis or other diseases that exhibit hyper-responsiveness to a variety of physiological and / or environmental stimuli. Specifically, the present invention provides methods for diagnosing asthma and chronic obstructive pulmonary disease, more specifically, asthma.

[0230] The present invention also provides methods for diagnosing non-small cell lung cancer. These methods include determining the expression level of at least one biomarker described herein, wherein the biomarker indicates the presence or development of non-small cell lung cancer. For example, the expression level of the biomarkers described herein can be used to determine the degree of progression of non-small cell lung cancer, the presence of precancerous lesions, or the staging of non-small cell lung cancer.

[0231] In a specific embodiment, the subject is selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer or reactive airway disease. Symptoms may include cough, shortness of breath, wheezing, chest pain, and coughing up blood; shoulder pain or vocal cord paralysis moving down the outside of the arm causing hoarseness; invasion of the esophagus may cause difficulty swallowing. If the large airways are obstructed, partial collapse of the lung may occur and cause infection leading to abscesses or pneumonia. Metastasis to the bone can cause extreme pain. Metastasis to the brain can cause neurological symptoms including dizziness, headaches, cramps, or symptoms commonly associated with stroke such as weakness or partial loss of sensation in the body. Lung cancer often produces symptoms caused by the production of hormone-like substances by tumor cells. A common paraneoplastic syndrome in NSCLC is the production of parathyroid hormone-like substances, which causes an increase in calcium in the bloodstream. Asthma generally produces symptoms such as cough (especially at night), wheezing, shortness of breath, and chest tightness, chest pain, or chest pressure. Therefore, many of the symptoms of asthma are clearly shared with NSCLC.

[0232] Approach to diagnosing reactive airway disease

[0233] The present invention is directed to methods of diagnosing reactive airway disease in individuals of various populations as described below. Generally, these methods rely on determining the extent of expression of specific biomarkers as described herein.

[0234] A. General Group

[0235] The present invention provides a method for diagnosing reactive airway disease in a subject, comprising (a) obtaining a physiological sample from the subject; and (b) determining the expression level of at least one biomarker from Table 2 in the subject, wherein the expression level of the at least one marker indicates reactive airway disease.

[0236] In a preferred embodiment, the present invention provides a method for diagnosing reactive airway disease in a subject, comprising determining the expression level of a plurality of biomarkers from Table 2 in a physiological sample of the subject, wherein the expression pattern of the plurality of markers indicates reactive airway disease or is associated with a change in the state of reactive airway disease. In another preferred embodiment, the expression pattern is associated with an increased likelihood that the subject has or may have reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 2. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods can be selected from the identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0237] In one embodiment, the subject is at risk for reactive airway disease. In one embodiment, the level of a specific biomarker associated with reactive airway disease is determined for an individual, and a level that is different from what is expected for a normal population indicates that the individual is "at risk". In another embodiment, the number of relevant biomarkers from Table 2 that are statistically deviated from normal is determined, with a greater number of deviating markers indicating a greater risk of reactive airway disease. In another embodiment, the subject is selected from those individuals who exhibit one or more symptoms of reactive airway disease.

[0238] In any of the above embodiments, preferred biomarkers for use in this method include at least one biomarker from Table 13B. More preferably, all biomarkers in this embodiment can be found in Table 13B.

[0239] B. Male group

[0240] The present invention provides a method for diagnosing reactive airway disease in a male subject, comprising (a) obtaining a physiological sample from the male subject; and (b) determining the expression level of at least one biomarker from Table 6 or 17 in the subject, wherein the expression level of the at least one marker indicates reactive airway disease.

[0241] In a preferred embodiment, the present invention provides a method for diagnosing reactive airway disease in a male subject, comprising determining the expression level of a plurality of biomarkers from Table 6 or 17 in a physiological sample of a male subject, wherein the expression pattern of the plurality of markers indicates reactive airway disease or is associated with a change in the state of reactive airway disease. In another preferred embodiment, the expression pattern is associated with an increased likelihood that the male subject has or may have reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 6 or 17. In fact, it should be clear that the plurality of biomarkers to be determined in these specific methods can be selected from the already identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0242] In one embodiment, the male subject is at risk for reactive airway disease. In one embodiment, the level of a specific biomarker associated with reactive airway disease is determined for a male individual, and a level that is different from what is expected for a normal male population indicates that the individual is "at risk". In another embodiment, the number of relevant biomarkers from Table 6 that are statistically deviated from normal is determined, and a larger number of deviating markers indicates a greater risk of reactive airway disease. In another embodiment, the male subject is selected from those individuals who exhibit one or more symptoms of reactive airway disease.

[0243] In another embodiment, the biomarkers used in this method comprise at least one biomarker from Table 13A.

[0244] C. Female groups

[0245] The present invention provides a method for diagnosing reactive airway disease in a female subject, comprising (a) obtaining a physiological sample from the female subject; and (b) determining the expression level of at least one biomarker from Table 10 or 21 in the subject, wherein the expression level of the at least one marker indicates reactive airway disease.

[0246] In a preferred embodiment, the present invention provides a method for diagnosing reactive airway disease in a female subject, comprising determining the expression level of a plurality of biomarkers from Table 10 or 21 in a physiological sample of a female subject, wherein the expression pattern of the plurality of markers indicates reactive airway disease or is associated with a change in the state of reactive airway disease. In another preferred embodiment, the expression pattern is associated with an increased likelihood that the female subject has or may have reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 10 or 21. In fact, it should be clear that the plurality of biomarkers to be determined in these specific methods can be selected from the already identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0247] In one embodiment, the female subject is at risk for reactive airway disease. In one embodiment, the level of a specific biomarker associated with reactive airway disease is determined for a female individual, and a level that is different from that expected for a normal female population indicates that the individual is "at risk". In another embodiment, the number of relevant biomarkers from Table 10 or 21 that are statistically deviated from normal is determined, and a larger number of deviating markers indicates a greater risk of reactive airway disease. In another embodiment, the female subject is selected from those individuals who exhibit one or more symptoms of reactive airway disease.

[0248] In another embodiment, the biomarkers used in this method comprise at least one biomarker from Table 13A.

[0249] Methods for diagnosing non-small cell lung cancer

[0250] The present invention is directed to methods for diagnosing non-small cell lung cancer in individuals of various populations as described below. Generally, these methods rely on determining the extent of expression of specific biomarkers as described herein.

[0251] A. General Group

[0252] The present invention provides a method for diagnosing non-small cell lung cancer in a subject, comprising (a) obtaining a physiological sample from the subject; and (b) determining the expression level of at least one biomarker from Table 3 in the subject, wherein the expression level of the at least one marker indicates the presence or development of non-small cell lung cancer.

[0253] In a preferred embodiment, the present invention provides a method for diagnosing non-small cell lung cancer in a subject, comprising determining the expression level of a plurality of biomarkers from Table 3 in a physiological sample of the subject, wherein the expression pattern of the plurality of markers indicates non-small cell lung cancer or is associated with a change in the disease state (i.e., clinical or diagnostic stage) of non-small cell lung cancer. In another preferred embodiment, the expression pattern is associated with an increased likelihood that the subject suffers from or may suffer from non-small cell lung cancer. The expression pattern can be characterized by any technique known in the field of pattern recognition technology. The plurality of biomarkers may include any combination of the biomarkers described above with reference to Table 3. In fact, it is clear that the plurality of biomarkers to be determined in these specific methods can be selected from the identified table using the criteria discussed above in the section entitled "Selecting biomarkers for determination".

[0254] In one embodiment, the subject is at risk for non-small cell lung cancer. In one embodiment, the level of a specific biomarker associated with non-small cell lung cancer is determined for an individual, and a level that is different from that expected for a normal population indicates that the individual is "at risk". In another embodiment, the number of relevant biomarkers from Table 3 that are statistically deviated from normal is determined, and a larger number of deviation markers indicates a greater risk of non-small cell lung cancer. In another embodiment, the subject is selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer.

[0255] In any of the above embodiments, preferred biomarkers for use in this method include at least one biomarker from Table 14B. More preferably, all biomarkers in this embodiment can be found in Table 14B.

[0256] B. Male group

[0257] The present invention also provides a method for diagnosing non-small cell lung cancer in a male subject, comprising (a) obtaining a physiological sample from the male subject; and (b) determining the expression level of at least one biomarker from Table 7 or 18 in the subject, wherein the expression level of the at least one marker indicates the presence and development of non-small cell lung cancer.

[0258] In a preferred embodiment, the present invention provides a method for diagnosing non-small cell lung cancer in a male subject, comprising determining the expression level of a plurality of biomarkers from Table 7 or 18 in a physiological sample of a male subject, wherein the expression pattern of the plurality of markers indicates non-small cell lung cancer or is associated with a change in a disease state (e.g., various stages) of non-small cell lung cancer. In another preferred embodiment, the expression pattern is associated with an increased likelihood that the male subject suffers from or may suffer from non-small cell lung cancer. The expression pattern can be characterized by any technique known in the field of pattern recognition technology. The plurality of biomarkers may include any combination of the biomarkers described above with reference to Table 7 or 18. In fact, it should be clear that the plurality of biomarkers to be determined in these specific methods can be selected from the identified table using the criteria discussed above in the section entitled "Selecting biomarkers for determination".

[0259] In one embodiment, male subjects are at risk of non-small cell lung cancer. In one embodiment, the level of specific biomarkers associated with non-small cell lung cancer in male individuals is determined, and the level that is different from the expected level of the normal male population indicates that this individual is "at risk". In another embodiment, the number of relevant biomarkers from Table 7 that are statistically deviated from normal is determined, and a larger number of deviation markers indicates a greater risk of non-small cell lung cancer. In another embodiment, male subjects are selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer.

[0260] In another embodiment, the biomarkers used in this method comprise at least one biomarker from Table 14A.

[0261] C. Female groups

[0262] The present invention also provides a method for diagnosing non-small cell lung cancer in a female subject, comprising (a) obtaining a physiological sample from the female subject; and (b) determining the expression level of at least one biomarker from Table 11 or 22 in the subject, wherein the expression level of the at least one marker indicates the presence or development of non-small cell lung cancer.

[0263] In a preferred embodiment, the present invention provides a method for diagnosing non-small cell lung cancer in a female subject, comprising determining the expression level of a plurality of biomarkers from Table 11 or 22 in a physiological sample of a female subject, wherein the expression pattern of the plurality of markers indicates non-small cell lung cancer or is associated with a change in a disease state (e.g., various stages) of non-small cell lung cancer. In another preferred embodiment, the expression pattern is associated with an increased likelihood that a female subject has or may have non-small cell lung cancer. The expression pattern can be characterized by any technique known in the field of pattern recognition technology. The plurality of biomarkers may include any combination of the biomarkers described above with reference to Table 11 or 22. In fact, it should be clear that the plurality of biomarkers to be determined in these specific methods can be selected from the identified table using the criteria discussed above in the section entitled "Selecting biomarkers for determination".

[0264] In one embodiment, female subjects have a risk of non-small cell lung cancer. In one embodiment, the level of specific biomarkers associated with non-small cell lung cancer in female individuals is determined, and the level that is different from the expected level of the normal female population indicates that this individual is "at risk". In another embodiment, the number of relevant biomarkers from Table 11 or 22 that are statistically deviated from normal is determined, and a larger number of deviation markers indicates a greater risk of non-small cell lung cancer. In another embodiment, female subjects are selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer.

[0265] In another embodiment, the biomarkers used in this method comprise at least one biomarker from Table 14A.

[0266] Methods for distinguishing non-small cell lung cancer from reactive airway disease

[0267] The present invention is directed to methods of diagnosing lung disease in various populations of individuals as described below. Generally, these methods rely on determining the extent of expression of specific biomarkers that distinguish between reactive airway disease and non-small cell lung cancer.

[0268] A. General Group

[0269] The present invention also provides a method for diagnosing a lung disease in a subject, comprising determining the expression level of at least one biomarker from Table 4 in the subject, wherein the expression level of at least one biomarker from Table 4 assists in distinguishing between an indication of reactive airway disease and non-small cell lung cancer. In one embodiment, the subject has been diagnosed as having reactive airway disease and / or non-small cell lung cancer. For example, the diagnosis has been determined by the expression level of at least one biomarker in a physiological sample of the subject, wherein the expression level of the at least one marker indicates reactive airway disease and / or non-small cell lung cancer.

[0270] The present invention also provides a method for diagnosing a lung disease in a subject, comprising (a) obtaining a physiological sample from the subject; and (b) determining the expression level of at least one biomarker from Table 4, at least one biomarker from Table 2, and at least one biomarker from Table 3 in the subject, wherein (i) the at least one biomarker from each of Table 2, Table 3, and Table 4 is not the same, (ii) the expression level of the at least one biomarker from Table 2 and Table 3 is indicative of reactive airway disease and non-small cell lung cancer, respectively, of the lung disease; and (iii) the expression level of the at least one biomarker from Table 4 assists in distinguishing between non-small cell lung cancer and reactive airway disease. Preferably, this method includes at least one marker from each table that is not present in any other table.

[0271] In a preferred embodiment, the method comprises determining the degree of expression of a plurality of biomarkers from Table 4, preferably also a plurality of biomarkers from Table 2, and a plurality of biomarkers from Table 3. In another preferred embodiment, the expression pattern is associated with an increased likelihood that the subject has non-small cell lung cancer or reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 2, Table 3, and Table 4. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods can be selected from the already identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0272] In one embodiment, the subject is at risk for non-small cell lung cancer and / or reactive airway disease. In another embodiment, the subject is selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer and / or reactive airway disease.

[0273] The present invention also provides a diagnostic method to assist in distinguishing the likelihood that a subject has a risk of developing or developing non-small cell lung cancer or reactive airway disease, comprising (a) obtaining a physiological sample from a subject at risk of developing non-small cell lung cancer or reactive airway disease; and (b) determining the expression level of at least one biomarker from Table 4 in the subject, wherein the expression level of at least one biomarker from Table 4 assists in distinguishing the likelihood that the subject has a risk of developing non-small cell lung cancer or reactive airway disease.

[0274] In a preferred embodiment, the method comprises determining the extent of expression of a plurality of biomarkers from Table 4. In another preferred embodiment, the expression pattern is associated with an increased likelihood that the subject has non-small cell lung cancer or reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 4. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods can be selected from the identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0275] In one embodiment, the subject is selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer or reactive airway disease.Methods related to "at risk" subjects are described above, and methods related thereto are encompassed by the present invention.

[0276] B. Male group

[0277] The present invention also provides a method for diagnosing a lung disease in a male subject, comprising determining the expression level of at least one biomarker from Table 8 or 19 in the subject, wherein the expression level of at least one biomarker from Table 8 or 19 assists in distinguishing between an indication of reactive airway disease and non-small cell lung cancer. In one embodiment, the male subject has been diagnosed with reactive airway disease and / or non-small cell lung cancer. For example, the diagnosis has been determined by the expression level of at least one biomarker in a physiological sample of the male subject, wherein the expression level of the at least one marker indicates reactive airway disease and / or non-small cell lung cancer.

[0278] The present invention also provides a method for diagnosing a lung disease in a male subject, comprising (a) obtaining a physiological sample from a male subject; and (b) determining the expression level of at least one biomarker from Table 8, at least one biomarker from Table 6, and at least one biomarker from Table 7 in the subject, wherein (i) the at least one biomarker from each of Table 6, Table 7, and Table 8 is not the same, (ii) the expression level of the at least one biomarker from Table 6 and Table 7 is indicative of reactive airway disease and non-small cell lung cancer, respectively, of the lung disease; and (iii) the expression level of the at least one biomarker from Table 8 assists in distinguishing between non-small cell lung cancer and reactive airway disease. Preferably, this method includes at least one marker from each table that is not present in any other table.

[0279] The present invention also provides a method for diagnosing a lung disease in a male subject, comprising (a) obtaining a physiological sample from a male subject; and (b) determining the expression level of at least one biomarker from Table 19, at least one biomarker from Table 18, and at least one biomarker from Table 17 in the subject, wherein (i) the at least one biomarker from each of Tables 17, 18, and 19 is not the same, (ii) the expression level of the at least one biomarker from Tables 17 and 18 is indicative of reactive airway disease and non-small cell lung cancer, respectively, of the lung disease; and (iii) the expression level of the at least one biomarker from Table 19 assists in distinguishing between non-small cell lung cancer and reactive airway disease. Preferably, this method includes at least one marker from each table that is not present in any other table.

[0280] In a preferred embodiment, the method comprises determining the degree of expression of a plurality of biomarkers from Table 8, preferably also a plurality of biomarkers from Table 6, and a plurality of biomarkers from Table 7. In another preferred embodiment, the expression pattern is associated with an increased likelihood of a male subject having non-small cell lung cancer or reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 6, Table 7, and Table 8. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods can be selected from the already identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0281] In a preferred embodiment, the method comprises determining the degree of expression of a plurality of biomarkers from Table 19, preferably also a plurality of biomarkers from Table 17, and a plurality of biomarkers from Table 18. In another preferred embodiment, the expression pattern is associated with an increased likelihood of a male subject having non-small cell lung cancer or reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 17, Table 18, and Table 19. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods can be selected from the already identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0282] In one embodiment, the male subject is at risk for non-small cell lung cancer and / or reactive airway disease. In another embodiment, the male subject is selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer and / or reactive airway disease.

[0283] The present invention also provides a diagnostic method to assist in distinguishing the likelihood that a male subject has a risk of developing or developing non-small cell lung cancer or reactive airway disease, comprising (a) obtaining a physiological sample from a male subject at risk of developing non-small cell lung cancer or reactive airway disease; and (b) determining the expression level of at least one biomarker from Table 8 or 19 in the subject, wherein the expression level of at least one biomarker from Table 8 or 19 assists in distinguishing the likelihood that the subject has a risk of developing non-small cell lung cancer or reactive airway disease.

[0284] In a preferred embodiment, the method comprises determining the extent of expression of a plurality of biomarkers from Table 8. In another preferred embodiment, the expression pattern is associated with an increased likelihood that a male subject has non-small cell lung cancer or reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Tables 8 or 19. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods can be selected from the identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0285] In one embodiment, the male subject is selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer or reactive airway disease.Methods related to "at risk" subjects are described above, and methods related thereto are encompassed by the present invention.

[0286] C. Female groups

[0287] The present invention also provides a method for diagnosing a lung disease in a female subject, comprising determining the expression level of at least one biomarker from Table 12 or 23 in the subject, wherein the expression level of at least one biomarker from Table 12 or 23 assists in distinguishing between an indication of reactive airway disease and non-small cell lung cancer. In one embodiment, the female subject has been diagnosed as having reactive airway disease and / or non-small cell lung cancer. For example, the diagnosis has been determined by the expression level of at least one biomarker in a physiological sample of the female subject, wherein the expression level of the at least one marker indicates reactive airway disease and / or non-small cell lung cancer.

[0288] The present invention also provides a method for diagnosing a lung disease in a female subject, comprising (a) obtaining a physiological sample from a female subject; and (b) determining the expression level of at least one biomarker from Table 12, at least one biomarker from Table 10, and at least one biomarker from Table 11 in the subject, wherein (i) the at least one biomarker from each of Tables 10, 11, and 12 is not the same, (ii) the expression level of the at least one biomarker from Tables 10 and 11 is indicative of reactive airway disease and non-small cell lung cancer, respectively, of the lung disease; and (iii) the expression level of the at least one biomarker from Table 12 assists in distinguishing between non-small cell lung cancer and reactive airway disease. Preferably, this method includes at least one marker from each table that is not present in any other table.

[0289] The present invention also provides a method for diagnosing a lung disease in a female subject, comprising (a) obtaining a physiological sample from the female subject; and (b) determining the expression level of at least one biomarker from Table 23, at least one biomarker from Table 21, and at least one biomarker from Table 22 in the subject, wherein (i) the at least one biomarker from each of Table 21, Table 22, and Table 23 is not the same, (ii) the expression level of the at least one biomarker from Table 21 and Table 22 is indicative of reactive airway disease and non-small cell lung cancer of the lung disease, respectively; and (iii) the expression level of the at least one biomarker from Table 23 assists in distinguishing between non-small cell lung cancer and reactive airway disease. Preferably, this method includes at least one marker from each table that is not present in any other table.

[0290] In a preferred embodiment, the method comprises determining the degree of expression of a plurality of biomarkers from Table 12, preferably also a plurality of biomarkers from Table 10, and a plurality of biomarkers from Table 11. In another preferred embodiment, the expression pattern is associated with an increased likelihood of a male subject having non-small cell lung cancer or reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 10, Table 11, and Table 12. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods can be selected from the already identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0291] In a preferred embodiment, the method comprises determining the degree of expression of a plurality of biomarkers from Table 23, preferably also a plurality of biomarkers from Table 21, and a plurality of biomarkers from Table 22. In another preferred embodiment, the expression pattern is associated with an increased likelihood that a male subject has non-small cell lung cancer or reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 21, Table 22, and Table 23. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods can be selected from the already identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0292] In one embodiment, the female subject is at risk for non-small cell lung cancer and / or reactive airway disease. In another embodiment, the female subject is selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer and / or reactive airway disease.

[0293] The present invention also provides a diagnostic method to assist in distinguishing the likelihood that a female subject has a risk of developing or developing non-small cell lung cancer or reactive airway disease, comprising (a) obtaining a physiological sample from a female subject at risk of developing non-small cell lung cancer or reactive airway disease; and (b) determining the expression level of at least one biomarker from Table 12 or 23 in the subject, wherein the expression level of at least one biomarker from Table 12 or 23 assists in distinguishing the likelihood that the subject has a risk of developing non-small cell lung cancer or reactive airway disease.

[0294] In a preferred embodiment, the method comprises determining the degree of expression of a plurality of biomarkers from Table 12 or 23. In another preferred embodiment, the expression pattern is associated with an increased likelihood that a female subject has non-small cell lung cancer or reactive airway disease. The expression pattern can be characterized by any technique known in the art of pattern recognition technology. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 12 or 23. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods can be selected from the already identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0295] In one embodiment, the female subject is selected from those individuals who exhibit one or more symptoms of non-small cell lung cancer or reactive airway disease.Methods related to "at risk" subjects are described above, and methods related thereto are encompassed by the present invention.

[0296] In any of the methods described herein that use biomarkers selected from more than one table to distinguish, for example, different disease states or different populations, analysis of biomarker results from individuals can be performed simultaneously or sequentially.

[0297] Methods of monitoring treatment

[0298] The present invention is directed to methods for monitoring treatment in individuals of the various populations described below. Generally, these methods rely on determining the extent of expression of specific biomarkers.

[0299] A. General Group

[0300] The present invention also provides a method for monitoring a subject, comprising (a) determining a first expression level of at least one biomarker from Table 1A in a sample obtained from the subject; (b) using a second sample obtained from the subject at a time different from the first expression level, determining a second expression level of at least one biomarker from Table 1A in the subject. ; And (d) comparing the first expression level and the second expression level. Generally, the subject has been subjected to a therapeutic intervention between the time when the first and second samples were obtained. Detecting changes in the expression pattern between the first and second determinations can be considered to reflect the effect of the therapeutic intervention. This embodiment can also be used to identify specific biomarkers that exhibit changes in their expression levels in response to specific therapeutic interventions.

[0301] In a preferred embodiment, the method comprises determining the extent of expression of a plurality of biomarkers from Table 1A. The plurality of markers may comprise any combination of the biomarkers described above with reference to Table 1A. In fact, it is to be understood that the plurality of biomarkers to be determined in these specific methods may be selected from the identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0302] The embodiments described above refer to the biomarkers of Table 1A. However, it is to be understood that in any of the described embodiments, the biomarkers of Table 1B, Table 1C, Table 2, Table 3, or Table 4 may be substituted for the biomarkers of Table 1A.

[0303] B. Male group

[0304] The present invention also provides a method for monitoring a male subject, comprising (a) determining the first expression level of at least one biomarker from Table 5A or 16A in a sample obtained from a male subject; (b) using a second sample obtained from a male subject at a time different from the first expression level, determining the second expression level of at least one biomarker from Table 1A or 16A in the male subject; and (d) comparing the first expression level and the second expression level. Generally, a therapeutic intervention has been performed on a male subject between the time when the first and second samples were obtained. Detecting changes in the expression pattern between the first and second determinations can be considered to reflect the effect of the therapeutic intervention. This embodiment can also be used to identify specific biomarkers that exhibit changes in their expression levels in response to specific therapeutic interventions.

[0305] In a preferred embodiment, the method comprises determining the extent of expression of a plurality of biomarkers from Table 5A or 16A. The plurality of markers may comprise any combination of the biomarkers described above with reference to Table 5A or 16A. Indeed, it is to be understood that the plurality of biomarkers to be determined in these specific methods may be selected from the identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0306] The embodiments described above refer to the biomarkers of Table 5A or 16A. However, it is to be understood that in any of the described embodiments, the biomarkers of Table 5B, Table 5C, Table 6, Table 7, Table 8, or Table 16B, Table 16C, Table 17, Table 18, or Table 19 may replace the biomarkers of Table 5A or 16A.

[0307] C. Female groups

[0308] The present invention also provides a method for monitoring a female subject, comprising (a) determining a first expression level in a sample obtained from a female subject of at least one biomarker from Table 9A or 20A in the female subject; (b) using a second sample obtained from the female subject at a time different from the first expression level, determining a second expression level in the female subject of at least one biomarker from Table 9A or 20A; and (d) comparing the first expression level and the second expression level. Generally, a therapeutic intervention has been performed on a female subject between the time when the first and second samples were obtained. Detecting changes in the expression pattern between the first and second determinations can be considered to reflect the effect of the therapeutic intervention. This embodiment can also be used to identify specific biomarkers that exhibit changes in their expression levels in response to specific therapeutic interventions.

[0309] In a preferred embodiment, the method comprises determining the extent of expression of a plurality of biomarkers from Table 9A or 20A. The plurality of markers may comprise any combination of the biomarkers described above with reference to Table 9A or 20A. Indeed, it is to be understood that the plurality of biomarkers to be determined in these specific methods may be selected from the identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0310] The embodiments described above refer to the biomarkers of Table 9A or 20A. However, it is to be understood that in any of the described embodiments, the biomarkers of Table 9B, Table 9C, Table 10, Table 11, Table 12, or Table 20B, Table 20C, Table 21, Table 22, or Table 23 may be substituted for the biomarkers of Table 9A or 20A. Methods of Predicting a Subject's Response to Therapeutic Intervention

[0311] The present invention is directed to methods for predicting a subject's response to a therapeutic intervention in individuals from various populations described below. Typically, these methods rely on determining the extent of expression of a particular biomarker.

[0312] A. General Group

[0313] The present invention also provides a method for predicting a subject's response to a therapeutic intervention, comprising (a) obtaining a physiological sample from a subject; and (b) determining the expression level of at least one biomarker from Table 1A in the subject, wherein the expression level of at least one biomarker from Table 1A assists in predicting the subject's response to the therapeutic intervention. Preferred biomarkers for this embodiment are those that show a response to the target therapeutic intervention by monitoring a subject population. This embodiment can also be used to select patients who are more likely to respond to treatment.

[0314] In a preferred embodiment, the method comprises determining the extent of expression of a plurality of biomarkers from Table 1A. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 1A. Indeed, it is to be understood that the plurality of biomarkers to be determined in these specific methods may be selected from the identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0315] The embodiments described above refer to the biomarkers of Table 1A. However, it is to be understood that the biomarkers of Table 1B, Table 1C, Table 2, Table 3 or Table 4 may be substituted for the biomarkers of Table 1A in any of the described embodiments.

[0316] B. Male group

[0317] The present invention also provides a method for predicting the response of a male subject to a therapeutic intervention, comprising (a) obtaining a physiological sample of a male subject; and (b) determining the expression level of at least one biomarker from Table 5A or 16A in the male subject, wherein the expression level of at least one biomarker from Table 5A or 16A assists in predicting the response of the male subject to the therapeutic intervention. Preferred biomarkers for this embodiment are those that show a response to the target therapeutic intervention by monitoring a male subject population. This embodiment can also be used to select male patients who are more likely to respond to treatment.

[0318] In a preferred embodiment, the method comprises determining the extent of expression of a plurality of biomarkers from Table 5A or 16A. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 5A or 16A. Indeed, it is to be understood that the plurality of biomarkers to be determined in these specific methods may be selected from the identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0319] The embodiments described above refer to the biomarkers of Table 5A or 16A. However, it is clear that the biomarkers of Table 5B, Table 5C, Table 6, Table 7, Table 8, Table 16B, Table 16C, Table 17, Table 18 or Table 19 can replace the biomarkers of Table 5A or 16A in any of the described embodiments.

[0320] C. Female groups

[0321] The present invention also provides a method for predicting the response of a female subject to a therapeutic intervention, comprising (a) obtaining a physiological sample from a female subject; and (b) determining the expression level of at least one biomarker from Table 9A or 20A in the female subject, wherein the expression level of at least one biomarker from Table 9A or 20A assists in predicting the response of the female subject to the therapeutic intervention. Preferred biomarkers for this embodiment are those that show a response to the target therapeutic intervention by monitoring a population of female subjects. This embodiment can also be used to select female patients who are more likely to respond to treatment.

[0322] In a preferred embodiment, the method comprises determining the extent of expression of a plurality of biomarkers from Table 9A or 20A. The plurality of biomarkers may comprise any combination of the biomarkers described above with reference to Table 9A or 20A. Indeed, it is to be understood that the plurality of biomarkers to be determined in these specific methods may be selected from the identified table using the criteria discussed above in the section entitled "Selecting Biomarkers for Determination".

[0323] The embodiments described above refer to the biomarkers of Table 9A or 20A. However, it is clear that the biomarkers of Table 9B, Table 9C, Table 10, Table 11, Table 12, Table 20B, Table 20C, Table 21, Table 22 or Table 23 can replace the biomarkers of Table 9A or 20A in any of the described embodiments.

[0324] Methods for designing kits

[0325] A. General Group

[0326] The present invention also provides a method for designing a kit for assisting in the diagnosis of a lung disease in a subject, comprising (a) selecting at least one biomarker from Table 1A; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit comprising the tool for determining the expression level.

[0327] The present invention also provides a method for designing a kit for diagnosing non-small cell lung cancer or reactive airway disease in a subject, comprising (a) selecting at least one biomarker from Table 1B; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0328] The present invention also provides a method for designing a kit for diagnosing non-small cell lung cancer or reactive airway disease in a subject, comprising (a) selecting at least one biomarker from Table 1C; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0329] The present invention also provides a method for designing a kit for diagnosing reactive airway disease in a subject, comprising (a) selecting at least one biomarker from Table 2; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0330] The present invention also provides a method for designing a kit for diagnosing non-small cell lung cancer in a subject, comprising (a) selecting at least one biomarker from Table 3; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0331] The present invention also provides a method for designing a kit for assisting in the diagnosis of a lung disease in a subject, comprising (a) selecting at least one biomarker from Table 4; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit comprising the tool for determining the expression level.

[0332] In the above method, steps (b) and (c) may alternatively be performed by the following steps: (b) selecting a detection reagent for detecting the at least one biomarker and (c) designing a kit comprising the detection reagent for detecting the at least one biomarker.

[0333] The present invention also provides methods for designing a kit, comprising selecting at least one biomarker from more than one table. For example, the present invention provides methods for designing a kit, comprising selecting at least one biomarker from Table 2 and selecting at least one biomarker from Table 3. In another example, the present invention provides methods for designing a kit, comprising selecting at least one biomarker from Table 2, selecting at least one biomarker from Table 3 and selecting at least one biomarker from Table 4. It is to be understood that these methods also comprise steps (b) and (c) as described above.

[0334] It will be appreciated that the various biomarkers to be assayed in these specific methods can be selected from the identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Assaying".

[0335] B. Male group

[0336] The present invention also provides a method for designing a kit for assisting in the diagnosis of lung disease in male subjects, comprising (a) selecting at least one biomarker from Table 5A or 16A; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0337] The present invention also provides a method for designing a kit for diagnosing non-small cell lung cancer or reactive airway disease in male subjects, comprising (a) selecting at least one biomarker from Table 5B or 16B; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0338] The present invention also provides a method for designing a kit for diagnosing non-small cell lung cancer or reactive airway disease in male subjects, comprising (a) selecting at least one biomarker from Table 5C or 16C; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0339] The present invention also provides a method for designing a kit for diagnosing reactive airway disease in male subjects, comprising (a) selecting at least one biomarker from Table 6 or 17; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0340] The present invention also provides a method for designing a kit for diagnosing non-small cell lung cancer in male subjects, comprising (a) selecting at least one biomarker from Table 7 or 18; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0341] The present invention also provides a method for designing a kit for assisting in the diagnosis of lung disease in male subjects, comprising (a) selecting at least one biomarker from Table 8 or 19; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0342] In the above method, steps (b) and (c) may alternatively be performed by the following steps: (b) selecting a detection reagent for detecting the at least one biomarker and (c) designing a kit comprising the detection reagent for detecting the at least one biomarker.

[0343] The present invention also provides a method for designing a kit, comprising selecting at least one biomarker from more than one table. For example, the present invention provides a method for designing a kit, comprising selecting at least one biomarker from Table 6 and selecting at least one biomarker from Table 7. In another example, the present invention provides a method for designing a kit, comprising selecting at least one biomarker from Table 6, selecting at least one biomarker from Table 7 and selecting at least one biomarker from Table 8. In another example, the present invention provides a method for designing a kit, comprising selecting at least one biomarker from Table 17 and selecting at least one biomarker from Table 18. In another example, the present invention provides a method for designing a kit, comprising selecting at least one biomarker from Table 17, selecting at least one biomarker from Table 18 and selecting at least one biomarker from Table 19. It is to be understood that these methods also include steps (b) and (c) as described above.

[0344] It will be appreciated that the various biomarkers to be assayed in these specific methods can be selected from the identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Assaying".

[0345] C. Female groups

[0346] The present invention also provides a method for designing a kit for assisting in the diagnosis of lung disease in female subjects, comprising (a) selecting at least one biomarker from Table 9A or 20A; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0347] The present invention also provides a method for designing a kit for diagnosing non-small cell lung cancer or reactive airway disease in female subjects, comprising (a) selecting at least one biomarker from Table 9B or 20B; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0348] The present invention also provides a method for designing a kit for diagnosing non-small cell lung cancer or reactive airway disease in female subjects, comprising (a) selecting at least one biomarker from Table 9C or 20C; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0349] The present invention also provides a method for designing a kit for diagnosing reactive airway disease in female subjects, comprising (a) selecting at least one biomarker from Table 10 or 21; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0350] The present invention also provides a method for designing a kit for diagnosing non-small cell lung cancer in female subjects, comprising (a) selecting at least one biomarker from Table 11 or 22; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0351] The present invention also provides a method for designing a kit for assisting in the diagnosis of lung disease in female subjects, comprising (a) selecting at least one biomarker from Table 12 or 23; (b) selecting a tool for determining the expression level of the at least one biomarker; and (c) designing a kit containing the tool for determining the expression level.

[0352] In the above method, steps (b) and (c) may alternatively be performed by the following steps: (b) selecting a detection reagent for detecting the at least one biomarker and (c) designing a kit comprising the detection reagent for detecting the at least one biomarker.

[0353] The present invention also provides a method for designing a kit, comprising selecting at least one biomarker from more than one table. For example, the present invention provides a method for designing a kit, comprising selecting at least one biomarker from Table 10 and selecting at least one biomarker from Table 11. In another example, the present invention provides a method for designing a kit, comprising selecting at least one biomarker from Table 10, selecting at least one biomarker from Table 11 and selecting at least one biomarker from Table 12. In another example, the present invention provides a method for designing a kit, comprising selecting at least one biomarker from Table 21 and selecting at least one biomarker from Table 22. In another example, the present invention provides a method for designing a kit, comprising selecting at least one biomarker from Table 21, selecting at least one biomarker from Table 22 and selecting at least one biomarker from Table 23. It is to be understood that these methods also include steps (b) and (c) as described above.

[0354] It will be appreciated that the various biomarkers to be assayed in these specific methods can be selected from the identified tables using the criteria discussed above in the section entitled "Selecting Biomarkers for Assaying".

[0355] Reagent test kit

[0356] The present invention provides kits comprising methods for determining the extent of expression of at least one biomarker described herein. The present invention also provides kits comprising detection reagents for detecting at least one biomarker described herein.

[0357] The invention provides kits comprising means for determining the extent of expression of at least one biomarker from Table 1A. The invention also provides kits comprising a detection reagent for detecting at least one biomarker from Table 1A.

[0358] The present invention also provides a kit comprising a method for determining the expression level of SEQ ID NO: 12. In one embodiment, the kit comprises means for determining the expression level of SEQ ID NO: 12 and any combination of SEQ ID NOs: 1-11 and 13-17.

[0359] The present invention also provides a kit comprising a detection reagent for detecting SEQ ID NO: 12. In one embodiment, the kit comprises a detection reagent for detecting SEQ ID NO: 12 and any combination of SEQ ID NOs: 1-11 and 13-17.

[0360] The present invention also provides a kit comprising means for determining the level of expression of at least one polypeptide selected from SEQ ID NOs: 1-17 and means for determining the level of expression of at least one biomarker from Table 1A.

[0361] The present invention also provides a kit comprising a detection reagent for detecting at least one polypeptide selected from SEQ ID NOs: 1-17 and a detection reagent for detecting at least one biomarker from Table 1A.

[0362] The embodiments described above refer to the biomarkers of Table 1A. However, it is to be understood that the biomarkers of Table 1A can be substituted with the biomarkers of Table 1B, Table 1C, Table 2, Table 3, Table 4, Table 5A, Table 5B, Table 5C, Table 6, Table 7, Table 8, Table 9A, Table 9B, Table 9C, Table 10, Table 11, Table 12, Table 16A, Table 16B, Table 16C, Table 17, Table 18, Table 19, Table 20A, Table 20B, Table 20C, Table 21, Table 22, or Table 23 in any of the described kits.

[0363] The present invention also provides a kit comprising (a) a first means for determining the expression level of at least one biomarker from Table 2; and (b) a second means for determining the expression level of at least one biomarker from Table 3, wherein the at least one biomarker from Table 2 and Table 3 are not the same.

[0364] The present invention also provides a kit comprising (a) a detection reagent for detecting at least one biomarker from Table 2; and (b) a detection reagent for detecting at least one biomarker from Table 3, wherein the at least one biomarker from Table 2 and Table 3 is not the same.

[0365] The present invention also provides a kit comprising (a) a first means for determining the expression level of at least one biomarker from Table 2; (b) a second means for determining the expression level of at least one biomarker from Table 3; and (c) a third means for determining the expression level of at least one biomarker from Table 4, wherein the at least one biomarker from Table 2, Table 3 and Table 4 is not the same.

[0366] The present invention also provides a kit comprising (a) a detection reagent for detecting at least one biomarker from Table 2; (b) a detection reagent for detecting at least one biomarker from Table 3; and (c) a detection reagent for detecting at least one biomarker from Table 4, wherein the at least one biomarker from Table 2, Table 3 and Table 4 is not the same.

[0367] The embodiments described above refer to the biomarkers of Table 2, Table 3, and Table 4. However, it is to be understood that the biomarkers of Table 6, Table 7, Table 8, Table 17, Table 18, or Table 19 may be substituted for the biomarkers of Table 2, Table 3, and Table 4, respectively, in any of the described kits. Further, it is to be understood that the biomarkers of Table 10, Table 11, Table 12, Table 21, Table 22, or Table 23 may be substituted for the biomarkers of Table 2, Table 3, and Table 4, respectively, in any of the described kits. Even further, the skilled artisan will understand that for any method requiring the detection of a specific plurality of biomarkers, the present invention contemplates a kit comprising means for detecting any combination of any of the biomarkers described above. It is also to be understood that the plurality of biomarkers to be determined described in these specific kits may be selected from the identified tables using the criteria discussed above in the section entitled "Selection of Biomarkers for Assay".

[0368] The following examples are provided to illustrate various modes of the invention disclosed herein, but are not intended to limit the invention in any way.

[0369] Example 1

[0370] Human blood samples were collected from volunteers. 30 samples were collected from individuals not known to have non-small cell lung cancer or asthma. These 30 samples comprise and are referred to herein as the "normal population". 28 blood samples were collected from individuals known to have asthma and diagnosed as such by a physician. These 28 samples comprise and are referred to herein as the "asthma population". 30 blood samples were collected from individuals known to have non-small cell lung cancer and diagnosed as such by a physician. These 30 samples comprise and are referred to herein as the "lung cancer population".

[0371] Studies were conducted to select biomarkers whose altered expression levels are thought to be associated with lung cancer or asthma. As used herein, "lung cancer" is intended to include those lung cancers known as non-small cell lung cancers. The following 59 biomarkers were selected for testing: CD40, hepatic growth factor ("HGF"), I-TAC ("CXCL11"; "chemokine (CXC motif) ligand 11," "interferon-induced T cell alpha chemoattractant"), leptin ("LEP"), matrix metalloproteinase ("MMP") 1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP12, MMP13, CD40 soluble ligand ("CD40 ligand"), epidermal growth factor ("EFG"), eosinophil activation Chemokine ("CCL11"), Fractalkine, Granulocyte Colony Stimulating Factor ("G-CSF"), Granulocyte Macrophage Colony Stimulating Factor ("GM-CSF"), Interferon γ ("IFNγ"), Interleukin ("IL") 1α, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, Mono MCP-1, MIP-1α, TGF-α, VEGF-α, GLP-1 / amylin (GLP-1 / amylin), glucagon, adiponectin, plasminogen activator inhibitor 1 (PAI-1, serine protease inhibitor 1) The proteins included sFas, sE-selectin, soluble vascular cell adhesion molecule (sVCAM), soluble intracellular adhesion molecule (sICAM), myeloperoxidase (MPO), C-reactive protein (CRP), serum amyloid A (SAA), and serum amyloid P (SAP).

[0372] Plasma samples from each of the normal, asthma, and lung cancer populations were screened for each of the 59 biomarkers by analyzing plasma samples using Luminex's xMAP technology, a quantitative multiplex immunoassay using automated bead-based technology.

[0373] Several different assay kits were used with Luminex xMAP technology to screen for biomarkers, namely Millipore's Human Cytokine / Chemokine (Cat#MPXHCYTO-60K), Human Endocrine (Cat#HENDO-65K), Human Serum Adipokines (Cat#HADKI-61K), Human Sepsis / Apoptosis (Cat#HSEP-63K), Human Cardiovascular Panel 1 (Cat#HCVD1-67AK) and Human Cardiovascular Panel 2 (HCVD2-67BK), R&D Systems, Inc.'s Human Fluorokine MAP Profiling BaseKit B (Cat#LUB00) and Human Fluorokine MAP MMP Profiling Base Kit (Cat#LMP000). Fluorescence intensity levels for each of the 59 biomarkers were recorded for each plasma sample from each population by multiplex immunoassay. The recorded fluorescence intensity is proportional to the concentration of the corresponding biomarker in the sample and to its expression level in the individual. The mean, standard deviation and relative standard deviation of the fluorescence intensity level associated with each biomarker for each population were calculated. Figures 1A-1C The mean, standard deviation and relative standard deviation of each biomarker in normal (NO), non-small cell lung cancer (LC) and asthma (AST) populations are shown.

[0374] The differences in inter-pathology between groups for each specific biomarker were then characterized using a Student's t-test. The mean fluorescence intensity measurements for each biomarker from normal patient samples were compared to those from samples from patients with lung cancer, and also compared to those derived from samples from patients with asthma. Figure 1D The differences between the various groups for each marker are shown. In addition, the mean fluorescence intensity measurements of lung cancer patients were compared with those of asthma patients and significance was estimated using Student's t statistic.

[0375] The statistical differences of each biomarker between normal, asthma and lung cancer groups were further analyzed. In order to qualitatively characterize the differences in the average expression level of each biomarker between the various groups, the student's t value was calculated using the t-test function available in the Microsoft EXCEL software package. Under the condition that the two-tail distribution has equal variance, the probability associated with the student's t value was calculated using the EXCEL t-test function.

[0376] The significance of the difference in expression levels between the groups was determined by the following criteria: any Student's t value with a probability of association less than 0.05 was considered significant and indicated the presence of a given pathological state, whether asthma or lung cancer. The use of a standard of 0.05 or lower is generally accepted in the scientific community. Any Student's t value with a probability of association greater than 0.1 was considered insignificant and could not indicate the presence of a given pathological state. Further, any Student's t value with a probability of association between 0.051-0.1 was determined to be marginally significant.

[0377] refer to Figure 1E , shows the Student's t value with the calculated associated probability for each biomarker comparing each group. It should be noted that Figure 1E The Student's t values ​​for the associated probabilities shown are calculated based on the assumption that the asthma, normal, and lung cancer populations have a single mean and a normal distribution.

[0378] The significance of the difference in biomarker expression levels is used to rank the relative importance of biomarkers. Those biomarkers that are found to be significantly different between each pathological state are classified as relatively more important. The measured values ​​of mean fluorescence intensity are checked, and the data of biomarkers that have no significant deviation from the mean intensity of all intensities and other population samples are excluded from further analysis. Those biomarkers with relatively low relative standard deviations are classified as more significant than those with relatively high standard deviations.

[0379] The relative significance of specific markers was evaluated without regard to the direction of deviation (i.e., whether the mean level of a specific marker was increased or decreased in any pathological state relative to any other pathological state). In this way, a set of biomarkers that exhibited high variability, relatively low relative standard deviation, and good instrument detectability (defined as non-zero uncorrected mean fluorescence intensity) between various pathological states was assembled. Those calculated results were used to test the efficacy of immunoassays and were analyzed to determine biomarkers that exhibited significant differences in expression levels between normal population expression levels, and were also used to determine reference ranges that were characteristic or associated with lung cancer and / or asthma pathological states.

[0380] Still reference Figure 1E, calculate the probability associated with the student's t value to compare the asthma population and the normal population. From the student's t probability of biomarkers sE-selectin, EGF, leptin, IL-5, PAI-1, resistin, MMP-13, CD40 ligand sVCAM-1, HGF, C-peptide, sICAM-1, MMP-7, adiponectin, GM-CSF and MIF, the significant difference between the asthma population and the normal population is determined. This determination is based on the student's t value associated probability of each of these biomarkers being less than 0.05 when comparing 28 samples from the asthma population with 30 samples from the normal population using the student's t function described herein. When the student's t probability of each of the biomarkers CRP, MMP-9, IL-4, IL-1α, SAA, IL-7 and IL-6 between the asthma population and the normal population is significantly greater than 0.05, the difference is determined to be insignificant.

[0381] If also Figure 1E As shown in , the probability associated with the student's t value is calculated to compare the lung cancer population with the normal population. The significant difference between the lung cancer population and the normal population is determined from the student's t probability of biomarkers sE-selectin, EGF, leptin, IL-5, PAI-1, resistin, CRP, MMP-9, IL-4, IL-1α, SAA, IL-7, CD40 ligand, MMP-7 and MMP-12. Once again, this determination is based on the student's t value associated probability of each of these biomarkers being less than 0.05 when comparing 30 samples from the lung cancer population with 30 samples from the normal population using the student's t function described herein. When the student's t probability of each of the biomarkers MMP-13, HGF, C-peptide, sICAM, adiponectin, GM-CSF, IL-17, TNFα, ITAC and MIF between the lung cancer population and the normal population is significantly greater than 0.05, the difference is determined to be insignificant.

[0382] The probability of the three markers being associated with Student's t values ​​between lung cancer and normal populations was only slightly greater than 0.05. Specifically, when comparing the lung cancer population to the normal population, the Student's t probability for IL-6 was 0.076195528, the Student's t probability for sVCAM-1 was 0.08869949, and the Student's t probability for IL-15 was 0.086324372. These biomarkers were considered to be not significantly different between the lung cancer population and the normal population. However, due to the fact that the Student's t probabilities for these three biomarkers were close to 0.05, it is possible that each marker varied significantly in the normal and lung cancer populations.

[0383] Finally, if Figure 1EAs shown, the lung cancer population and the asthma population are compared by calculating the probability associated with the student's t value. The significant difference between the lung cancer population and the asthma population is determined from the student's t probability of the biomarkers sE-selectin, EGF, leptin, IL-5, PAI-1, resistin, CRP, MMP-9, IL-4, IL-1α, SAA, IL-7, IL-6, MMP-13, sVCAM, HGF, C-peptide, sICAM, adiponectin, GM-CSF, IL-17, IL-15, TNFα and I-TAC. This determination is based on the student's t value associated probability of each of these biomarkers being less than 0.05 when comparing 30 samples from the lung cancer population with 28 samples from the asthma population using the student's t function described herein. When the student's t probability of each of the biomarkers CD40 ligand, MMP-7, MMP-12 and MIF between the lung cancer population and the asthma population is significantly greater than 0.05, the difference is determined to be insignificant.

[0384] Example 2

[0385] Human blood samples were collected from volunteers. 142 samples were collected from individuals not known to have non-small cell lung cancer or asthma. These samples comprise and are referred to herein as the "normal population". 108 blood samples were collected from individuals known to have asthma and diagnosed as such by a physician. These samples comprise and are referred to herein as the "asthma population". 146 blood samples were collected from individuals known to have non-small cell lung cancer and diagnosed as such by a physician. These samples comprise and are referred to herein as the "lung cancer population".

[0386] The same procedure as described in Example 1 was carried out. Figure 2A-2E The results obtained are shown. These results provide guidance for selecting suitable biomarkers for use in the methods of the present invention. In particular, the probability values ​​of specific markers are useful in this regard.

[0387] Figure 2E The probabilities associated with the effectiveness of various biomarkers for distinguishing physiological states of different populations are shown. Probability values ​​of 0.1 or less are highlighted on this table to identify target biomarkers. Biomarker probability values ​​for preferred methods of the present invention are 0.05 or less, more preferably 0.01, and even more preferably 0.001 or less.

[0388] Example 3

[0389] Human blood samples were collected from volunteers. 288 samples were collected from individuals not known to have non-small cell lung cancer or asthma. These samples comprise and are referred to herein as the "normal population". 180 blood samples were collected from individuals known to have asthma and diagnosed as such by a physician. These samples comprise and are referred to herein as the "asthma population". 360 blood samples were collected from individuals known to have non-small cell lung cancer and diagnosed as such by a physician. These samples comprise and are referred to herein as the "lung cancer population".

[0390] The same method as described in Example 1 was performed. Panomics' Procarta Cytokine kit (Cat# PC1017) was also used. Antibodies to PAI-1 and leptin from two different kits were used. PAI-1 A and leptin 1 The antibody was produced by Millipore. PAI-1 B The antibodies were produced by Panomics. Figures 3A-3E The results obtained are displayed. These results provide guidance for selecting biomarkers suitable for the method of the present invention. In particular, the probability values ​​of specific markers are useful in this regard.

[0391] Figure 3E The probabilities associated with the effectiveness of various biomarkers for distinguishing different population physiological states are shown. Probability values ​​at or below 0.1 are highlighted on this table to identify target biomarkers. Biomarker probability values ​​for preferred methods of the present invention are 0.05 or below, more preferably 0.01, and even more preferably 0.001 or below.

[0392] The data were then pooled and analyzed by gender.

[0393] Figures 4A-4C Mean fluorescence intensity levels of biomarkers in normal (NO), non-small cell lung cancer (LC), and asthma (AST) female populations are shown. Figure 4D The percent change in the mean for each biomarker in the AST vs. NO female population, the LC vs. NO female population, and the AST vs. LC female population is shown. Figure 4E Probabilities associated with Student's t values ​​calculated by comparing the mean fluorescence intensity of each biomarker measured for the AST vs. NO female population, the LC vs. NO female population, and the AST vs. LC female population, respectively, are shown.

[0394] The same information for the male population is shown in Figures 5A-5E .

[0395] Next, compare the data for the female and male groups. Fig. 6AThe percent change in the mean of each biomarker is shown for the AST male group compared to the AST female group, the LC male group compared to the LC female group, and the NO male group compared to the NO female group. Figure 6B Probabilities associated with Student's t values ​​calculated by comparing the mean fluorescence intensity of each biomarker measured in the male and female populations from Example 3 are shown, where the mean values ​​to be compared are the AST male and female populations, the LC male and female populations, and the NO male and female populations, respectively.

[0396] Example 4

[0397] The Kruskal Wallis test is a well-known nonparametric statistical method. The data obtained from Example 3 were pooled according to gender and analyzed using the Kruskal Wallis (U test). Markers with a probability value of 0.05 or less were considered significant. Markers showing marginally significant differences (probability between 0.051-0.10) and insignificant differences (probability above 0.10) were discarded. The results of the retained markers are shown in Figures 7-8.

[0398] Fig. 7A The percentage change in the mean concentration of each biomarker for the LC vs. NO female population, AST vs. NO female population, and AST vs. LC female population is shown. A pure sum (i.e., the sum of the absolute values ​​of the percentage change in all three comparisons) is also provided and used to rank the biomarkers. Figure 7B Shown are the probabilities associated with the KruskalWallis test calculated by comparing the concentrations of each biomarker, where the groups to be compared are AST vs. NO female group, LC vs. NO female group, and AST vs. LC female group, respectively.

[0399] The same information for the male population is shown in Fig. 8A and 8B .

[0400] Biomarkers showed unique sex- and disease-specific patterns. When single-sex analysis was performed on LC, 36 markers were identified with a cutoff threshold of at least 25% absolute change and 32 markers with a cutoff threshold of at least 50%. For females, 32 markers with at least 25% cutoff and 30 markers with at least 50% cutoff were found. For males, 39 markers with at least 25% cutoff and 37 markers with at least 50% cutoff were found. For females, the expression of four markers was unique in LC compared to NO: IL-8 and serum amyloid P (downregulated), serum amyloid A and C-reactive protein (both upregulated). For males, the expression of five markers was unique in LC compared to NO: growth hormone (downregulated), matrix metalloproteinases-7 and -8, resistin and liver growth factor (all upregulated). Three markers showed opposite expression patterns: (i) VEGF was downregulated in females and upregulated in males in LC compared with NO; (ii) leptin was upregulated in females and downregulated in males; (iii) MIP-1a was upregulated in males and downregulated in females in LC versus NO.

[0401] The present invention provides a variety of methods for identifying disease states based on sex. For example, the present invention provides methods for performing physiological qualitative characterization in male subjects, including determining whether growth hormone is downregulated, and / or whether matrix metalloproteinases-7 and -8, resistin and liver growth factor are upregulated. These patterns indicate disease. The assays included in the present invention include detecting abnormal up / down regulation of three, four or five of these biomarkers in male subjects.

[0402] In another example, the invention provides a method for physiological characterization in a female subject, comprising determining whether IL-8 and / or serum amyloid beta are downregulated, and / or whether serum amyloid A and C-reactive protein are upregulated. These patterns are indicative of disease. The assays encompassed by the invention include detecting abnormal up / down regulation of three or four of these biomarkers in a female subject.

[0403] Example 5

[0404] Human blood samples are collected from volunteers. 30 samples are collected from individuals who are not known to suffer from non-small cell lung cancer or asthma. These individuals who are not known to suffer from non-small cell lung cancer or asthma are included and referred to as "normal populations" in this article. 28 blood samples are collected from individuals known to suffer from asthma and diagnosed as such by a physician. Individuals known to suffer from asthma are included and referred to as "asthma populations" in this article. 30 blood samples are collected from individuals known to suffer from non-small cell lung cancer and diagnosed as such by a physician. Individuals known to suffer from non-small cell lung cancer are included and referred to as "lung cancer populations" in this article. Typically, as used herein, the term "lung cancer" or "multiple lung cancers" means non-small cell lung cancer.

[0405] 8-10 plasma samples from each of the asthma population, normal population, and lung cancer population were randomly selected for testing. Each sample from each population was subjected to the action of a protease or digestion reagent. Trypsin was used as a protease, and it is highly desirable to use it as a protease because of its ability to produce highly specific and highly predictable cuts (this is because trypsin is known to hydrolyze peptide chains at the carboxyl termini of lysine and arginine, unless there is a proline immediately following the lysine or arginine). Although trypsin was used, other proteases or digestion reagents may also be used. It is desirable to use a protease or protease mixture that is at least as specific as trypsin in hydrolysis.

[0406] Tryptic peptides (peptides formed after trypsin cleavage) were then separated from insoluble materials by centrifugation of the sample and capillary liquid chromatography using a water acetonitrile gradient with 0.1% formic acid using a 0.375X180mm Supelcosil ABZ+ column on an Eksigent 2D capillary HPLC to provide chromatographic resolution of the produced tryptic peptides. Separation of the peptides is necessary because the electrospray ionization process is subject to ion co-suppression, where ion species with higher proton affinity suppress ion formation of ions with lower proton affinity when eluted simultaneously from the electrospray emitter, which in this case is co-terminal with the end of the HPLC column.

[0407] This methodology enables chromatographic separation of the large number of peptides produced in tryptic digestion and helps minimize co-suppression problems, thus maximizing the chance of pseudo-molecular ion co-suppression formation, thereby maximizing ion sampling. The tryptic peptides of each sample are then subjected to LC-ESIMS. LC-ESIMS separates the individual peptides in each sample in time by passing the peptides in each sample through a column consisting of a solvent system of water, acetonitrile and formic acid as described above.

[0408] The peptide is then sprayed with an electrospray ion source so that the peptide is ionized and produces peptide pseudomolecular ions as described above. The peptide is passed through the mass spectrometer in the LC-ESIMS, where the molecular mass is measured with regard to each peptide pseudomolecular ion. After passing through LC-ESIMS, mass spectrum readings are produced for the peptide present in each sample from mass spectrum data, i.e., intensity, molecular weight and elution time of the peptide. Mass spectrum readings are generally graphical illustrations of the peptide pseudomolecular ion signals recorded by LC-ESIMS, where the x-axis is the mass-to-charge ratio measured, and the y-axis is the signal intensity of the pseudomolecular ion signals. These data are then processed by the software system controlling LC-ESIMS and the resulting data are obtained and stored.

[0409] Once mass spectral data is obtained and placed on mass spectral readings, comparative analysis is performed, wherein the mass spectral readings of each serum sample tested in LC-ESIMS are performed for each population interpathologically and intrapathologically. Mass spectral peaks are compared between each sample tested in a normal population. Mass spectral peaks are then compared between each sample tested in an asthma population and a lung cancer population. After performing intrapathological comparisons, comparisons between pathological states are performed, wherein the mass spectral readings of each sample tested in LC-ESIMS for an asthma population are compared with each sample tested in a normal population. Similarly, the mass spectral readings of each sample tested in LC-ESIMS for a lung cancer population are compared with each sample tested in a normal population.

[0410] Peptides with mass spectrometry readings indicating that the peptide intensity is inconsistently differentially expressed or substantially unchanged within the pathological state (less than 10-fold variance in intensity) when comparing the asthma population or lung cancer population to the normal population are determined to be insignificant and excluded. Typically, the exclusion criteria used include: for a given protein, the peptide peak intensities of at least half of the identified characteristic peptides are compared on at least 10 data sets derived from analysis of individual patient sera from each pathological state. If the intensities of the majority of peptide peaks derived from a given protein are at least 10-fold higher in intensity for 80% of the serum data sets, the protein is classified as differentially regulated between the two pathological state categories.

[0411] However, the identity of the protein that produces the peptide observed to be differentially regulated is unknown and needs to be identified. To perform the identification of the protein, the peptide pseudomolecule ion signal intensity is compared across a known database containing a library of known proteins and peptides as well as suspected proteins and peptides.

[0412] The mass spectrometry readings of the tryptic digests of each sample from each normal, lung cancer and asthma colonies are input into a known search engine called Mascot. Mascot is a search engine known in the art that uses mass spectrometry data to identify proteins from four major sequencing databases, i.e. MSDB, NCBInr, SwissProt and dbEST databases. These databases contain all proteins of known sequences and information on all inferred proteins based on observations of the characteristic protein transcription initiation region that is derived from the gene sequence. These databases are continuously checked with regard to accuracy and redundancy and continuously added to identify and publish as new proteins and gene sequences in science and patent documentation.

[0413] The search criteria and parameters are entered into the Mascot program, and the mass spectral data from each population mass spectrometry reading is run through the Mascot program. The mass spectral data entered into the Mascot program is used for all samples of each pathological state. The Mascot program then runs the mass spectral data of the entered peptides against a sequencing database, comparing the peak intensity and mass of each peptide with the masses and peak intensities of known peptides and proteins. Mascot then generates a search result that returns a list of candidates for possible protein identification matches (usually referred to as "significant matches" for each sample analyzed).

[0414] Significant matches were determined by the Mascot program by assigning a score called the "Mowse score" to each sample tested. The Mowse score is an algorithm where the score is -10*LOG 10 (P), where P is the probability that the observed match is a random event, which is associated with a significance p-value where p is less than 0.05, which is a generally accepted standard in the scientific community. Mowse scores of about 55 to about 66 or above are generally considered significant. The significance level varies slightly due to specific search considerations and database parameters. The significant matches are returned for each peptide run, generating a candidate list of proteins.

[0415] Next, comparative analysis was performed using the same method as described in US20090069189, which is incorporated herein by reference in its entirety.

[0416] Data from mass spectrometry readings are cross-checked with the significant matches to verify raw data, peak characteristics, charge multiplicity, isotope distribution and flanking charge states. Then reverse search is performed to add peptides to the candidate list, which may be missed by the automatic search of the Mascot program. The added peptides are identified by selecting the "best match" of a single protein that is substantially matched with each parameter of the compared peptide, performing computer digestion, wherein the tryptic peptides and their respective molecular masses are calculated based on known amino acids or gene sequences of proteins. Then the peptide masses of these predictions are searched for the raw mass spectrometry data, and any peak identified is checked and qualified as described above. Then, all peptides, including those identified automatically by Mascot and identified by manual inspection, are entered into the mass list used by Mascot. As described below herein, the refined matching is then used to derive the refined Mowse score.

[0417] As a result of the identification process, protein arginase-1 was determined to be expressed with significant differences between asthma populations, lung cancer populations and / or normal populations. Other proteins identified using this method are BAC04615, Q6NSC8, CAF17350, Q6ZUD4, Q8N7P1, CAC69571, protein 4 comprising a FERM domain, JCC1445 proteasome endopeptidase complex chain C2 long splice form, syntaxin 11, AAK13083 and AAK130490. See the same method described in US20090069189 for comparative analysis, which is incorporated herein by reference in its entirety.

[0418] Specific proteins that are consistently differentially expressed in patients with asthma and lung cancer have been identified, making it possible to diagnose these pathological conditions early in the progression of the disease by subjecting proteins in patient plasma to trypsin digestion and analysis by LC-ESIMS, obtaining mass spectrometry data, and determining whether the mass spectrometry data includes peaks for one or more of arginase-1, BAC04615, Q6NSC8, CAF17350, Q6ZUD4, Q8N7P1, CAC69571, FERM domain-containing protein 4, JCC1445 proteasome endopeptidase complex chain C2 long splice form, syntaxin 11, AAK13083, and AAK130490. The levels of any protein found in the patient sample are then compared to the levels found in a normal population.

[0419] The amino acid sequence disclosed in SEQ ID NO: 1 is the primary amino acid sequence of protein BAC04615 known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO: 2 is the primary amino acid sequence of protein Q6NSC8 known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO: 3 is the primary amino acid sequence of protein CAF17350 known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO: 4 is the primary amino acid sequence of protein Q6ZUD4 known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO: 5 is the primary amino acid sequence of protein 4 containing a FERM domain known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO: 6 is the primary amino acid sequence of protein AAK13083 known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO: 7 is the primary amino acid sequence of protein Q8N7P1 known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO:8 is the primary amino acid sequence of the protein CAC69571 known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO:9 is the primary amino acid sequence of the protein JCC1445 proteasome endopeptidase complex chain C2 long splice known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO:10 is the primary amino acid sequence of the protein syntaxin 11 known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO:11 is the primary amino acid sequence of the protein AAK13049 known as of the date of filing this application. The amino acid sequence disclosed in SEQ ID NO:12 is the primary amino acid sequence of the protein arginase-1 known as of the date of filing this application.

[0420] Example 6

[0421] Selected tissue samples from asthma patients were subjected to the same method described in Example 5. See also Application No. 61 / 176,437, which is incorporated herein by reference in its entirety.

[0422] As a result of the identification process, the following proteins were determined to be significantly differentially expressed in asthma patients:

[0423]

[0424] Five specific proteins have been identified that are consistently differentially expressed in asthma patients, making it possible to diagnose these pathological conditions early in the progression of the disease by subjecting proteins in patient tissue plasma to trypsin digestion and analysis by LC-ESIMS, obtaining mass spectrometry data, and determining whether the mass spectrometry data includes a peak of one or more of SEQ ID NOs: 13 to 17. The level of any protein found in the patient sample is then compared to the level found in a normal population.

[0425] Example 7

[0426] Diagnostic Tests for Non-Small Cell Lung Cancer

[0427] The biological fluid sample is obtained from the patient for whom diagnostic information needs to be obtained. The sample is preferably serum or plasma. The concentrations of 7 of the following 14 biomarkers are determined in the sample: IL-13, I-TAC, MCP-1, MMP-1, MPO, HGF, eotaxin, MMP-9, MMP-7, IP-10, SAA, resistin, IL-5 and sVACM-1. The concentration measured for each biomarker from the sample is compared with the concentration range of this marker found in the same liquid of a normal individual, a group of individuals diagnosed with asthma, a group of individuals diagnosed with asthma and a group of individuals diagnosed with NSCLC. Deviations from the normal range indicate lung disease, and deviations from the range of the group of individuals suffering from asthma indicate NSCLC. Testing of patients using biomarkers from the same group of 14 markers can be used for the diagnosis of asthma or other reactive airway diseases in similar steps.

[0428] Example 8

[0429] Monitoring treatment for non-small cell lung cancer

[0430] A pre-treatment sample of a biological fluid is obtained from a patient who has been diagnosed with NSCLS before any treatment of the disease. The sample is preferably serum or plasma. The concentrations of 8 of the following 24 biomarkers are determined in the sample: IL-13, EGF, I-TAC, MMP-1, IL-12 (p70), eotaxin, MMP-8, MCP-1, MPO, IP-10, SAA, HGF, MMP-9, MMP-12, amylin (total), MMP-7, IL-6, MIL-1β, adiponectin, IL-10, IL-5, IL-4, SE-selectin, and MIP-1α. The concentrations measured for each biomarker from the sample can be compared to the concentration range of this marker found in the same fluid of a normal human individual. After the pre-treatment sample has been obtained, the patient undergoes therapeutic intervention, including surgery, followed by radiotherapy. A sample of the same fluid is obtained after surgery but before radiotherapy. Additional samples were obtained after each course of radiation therapy. The concentrations of the same eight biomarkers were determined in each sample. Changes in the expression levels of each marker were recorded and compared with other signs of disease progression.

[0431] Example 9

[0432] Selecting predictive biomarkers

[0433] A pre-treatment sample of a biological fluid is obtained from a patient who has been diagnosed with NSCLS before any treatment of the disease. The sample is preferably serum or plasma. The concentrations of the following 24 biomarkers are determined in the sample: IL-13, EGF, I-TAC, MMP-1, IL-12 (p70), eotaxin, MMP-8, MCP-1, MPO, IP-10, SAA, HGF, MMP-9, MMP-12, amylin (total), MMP-7, IL-6, MIL-1β, adiponectin, IL-10, IL-5, IL-4, SE-selectin and MIP-1α. The concentration measured for each biomarker from the sample is compared with the concentration range of this marker found in the same fluid of a normal human individual. After the pre-treatment sample has been obtained, the patient undergoes therapeutic intervention, including surgery, followed by radiotherapy. A sample of the same fluid is obtained after surgery but before radiotherapy. Additional samples are obtained after each course of radiotherapy. The concentrations of these 24 biomarkers were determined in each sample. Changes in the expression levels of each marker were recorded and compared with other signs of disease progression. All biomarkers whose levels changed after treatment were identified.

[0434] Example 10

[0435] Select suspected patients

[0436] A sample of a biological fluid is obtained from a patient who has been diagnosed with NSCLS. The sample is preferably serum or plasma. The concentration of each biomarker identified in the previous examples is determined in the sample, and the patient who shows the greatest number of biomarkers that deviate from normal values ​​is selected for treatment.

[0437] Embodiment 11

[0438] Diagnostic tests for non-small cell lung cancer in men

[0439] A sample of biological fluid is obtained from a male patient whose diagnostic information is needed. The sample is preferably serum or plasma. The concentrations of 7 of the following 14 biomarkers are determined in the sample: I-TAC, MPO, HGF, MMP-1, MMP-8, eotaxin, IL-8, MMP-7, IP-10, sVACM-1, IL-10, adiponectin, SAP and IFN-γ. The concentration measured for each biomarker from the sample is compared with the concentration range of this marker found in the same fluid of a normal male individual, a group of male individuals diagnosed with asthma, and a group of male individuals diagnosed with NSCLC. Deviations from the normal range indicate lung disease, and deviations from the range of groups suffering from asthma indicate NSCLC. Testing of patients using the same group of biomarkers from 14 can be used for the diagnosis of asthma or other reactive airway diseases in similar steps.

[0440] Example 12

[0441] Alternative non-small cell lung cancer tests in men

[0442] Many, if not all, of the biomarkers identified in Tables 1-15 participate in the communication pathways described above. Some of these biomarkers are related to each other as first order interactors. The use of known relationships between specific biomarkers and their first order interactors facilitates the selection of markers for use in diagnostic or predictive assays. The known communication relationships between the biomarkers listed in Table 16B can be found in Fig. 9 , which is generated by the Ariadne system. Fig. 9The first-order interactors of HGF (liver growth factor) are shown, including sFasL (soluble Fas ligand), PAI-1 (serine proteinase inhibitor 1) (active / total), Ins (growth hormone; which also includes C-peptide), EGF (epidermal growth factor), MPO (myeloperoxidase) and MIF (macrophage migration inhibitory factor). Other interactors (non-first-order) include RETN (resistin, xcp1), SAA1 (serum amyloid A, SAA), CCL11 (eotaxin), LEP (leptin) and CXCL11 (chemokine (CXC domain) ligand 11, interferon-induced T cell alpha chemoattractant (I-TAC) or interferon gamma-induced protein 9 (IP-9)). In addition, Fig. 9 It was shown that the two biomarkers MMP1 and MMP-8 (matrix metalloproteinases 1 and 8) were not in the same communication pathway with HGF.

[0443] One way to maximize the information gathered by measuring a selected set of biomarkers is to select a plurality of biomarkers such that the set includes biomarkers that are not in the same communication pathway. Using the list of biomarkers in Table 16B, it appears that if at least the levels of HGF or another biomarker of a first order interactor of HGF and MMP-8 are abnormal in a male subject, the likelihood that the subject has lung cancer is much higher. If the level of MMP-1 is also abnormal, the likelihood is even higher. Thus, a method according to the invention for diagnosing lung cancer in a male subject is to determine the levels of at least HGF or another biomarker of a first order interactor of HGF and MMP-8 and compare to the range expected for a normal population to see if the levels of these biomarkers are abnormal. In a preferred mode, the diagnostic method further includes determining whether the level of MMP-1 is normal. More preferably, one or more of CXCL11, LEP, SAA1 and / or RETN are also determined, and their levels are compared to the range expected for a normal population of individuals. The more of these biomarkers are present at abnormal levels, the more likely the subject is to have lung cancer.

[0444] Example 13

[0445] Monitoring treatment for non-small cell lung cancer in men

[0446] A pre-treatment sample of a biological fluid is obtained from a male patient who has been diagnosed with NSCLS before any treatment of the disease. The sample is preferably serum or plasma. The concentrations of 8 of the following 24 biomarkers are determined in the sample: IL-13, I-TAC, EGF, MPO, HGF, MMP-1, MMP-8, MIF, eotaxin, IL-12 (p70), MCP-1, MMP-9, SAA, IP-10, amylin (total), MMP-7, resistin, IL-6, MIP-1β, TNFα, IL-8, IL-5, CRP and IL-10. The concentration measured for each biomarker from the sample can be compared with the concentration range of this marker found in the same fluid of a normal individual. After the pre-treatment sample has been obtained, the patient undergoes therapeutic intervention, including surgery, followed by radiotherapy. Samples of the same fluid are obtained after surgery but before radiotherapy. Additional samples are obtained after each radiotherapy course. The concentrations of the same eight biomarkers were determined in each sample. Changes in the expression levels of each marker were recorded and compared with other signs of disease progression.

[0447] Embodiment 14

[0448] Selecting predictive biomarkers

[0449] A pre-treatment sample of a biological fluid is obtained from a patient who has been diagnosed with NSCLS before any treatment of the disease. The sample is preferably serum or plasma. The concentrations of the following 24 biomarkers are determined in the sample: IL-13, I-TAC, EGF, MPO, HGF, MMP-1, MMP-8, MIF, eotaxin, IL-12 (p70), MCP-1, MMP-9, SAA, IP-10, amylin (total), MMP-7, resistin, IL-6, MIP-1β, TNF-α, IL-8, IL-5, CRP and IL-10. The concentration measured for each biomarker from the sample is compared with the concentration range of this marker found in the same fluid of a normal individual. After the pre-treatment sample has been obtained, the patient undergoes therapeutic intervention, including surgery, followed by radiotherapy. Samples of the same fluid are obtained after surgery but before radiotherapy. Additional samples are obtained after each course of radiotherapy. The concentrations of these 24 biomarkers were determined in each sample. Changes in the expression levels of each marker were recorded and compared with other signs of disease progression. All biomarkers whose levels changed after treatment were identified.

[0450] Embodiment 15

[0451] Select suspected patients

[0452] A sample of biological fluid is obtained from a patient who has been diagnosed with NSCLS. The sample is preferably serum or plasma. The concentration of each biomarker identified in the previous examples is determined in the sample, and the patient who shows the greatest number of biomarkers that deviate from normal values ​​is selected for treatment. Sequence Listing <110> Cancer Prevention and Treatment Ltd. <120> Methods and kits for identifying, evaluating, preventing and treating lung diseases <130> 147140F31PWCN <140> PCT / US2010 / 27243 <141> 2010-03-12 <150> 61 / 237,198 <151> 2009-08-26 <150> 12 / 403,369 <151> 2009-03-12 <160> 17 <170> PatentIn version 3.3 <210> 1 <211> 319 <212> PRT <213> Homo sapiens <400> 1 Met Val Leu Ser Glu Leu Ala Ala Arg Leu Asn Cys Ala Glu Tyr 5 10 15 Lys Asn Trp Val Lys Ala Gly His Cys Leu Leu Leu Leu Arg Ser 20 25 30 Cys Leu Gln Gly Phe Val Gly Arg Glu Val Leu Ser Phe His Arg 35 40 45 Gly Leu Leu Ala Ala Ala Pro Gly Leu Gly Pro Arg Ala Val Cys 50 55 60 Arg Gly Gly Ser Arg Cys Ser Pro Arg Ala Arg Gln Phe Gln Pro 65 70 75 Gln Cys Gln Val Cys Ala Glu Trp Lys Arg Glu Ile Leu Arg His 80 85 90 His Val Asn Arg Asn Gly Asp Val His Trp Gly Asn Cys Arg Pro 95 100 105 Gly Arg Trp Pro Val Asp Ala Trp Glu Val Ala Lys Ala Phe Met 110 115 120 Pro Arg Gly Leu Ala Asp Lys Gln Gly Pro Glu Glu Cys Asp Ala 125 130 135 Val Ala Leu Leu Ser Leu Ile Asn Ser Cys Asp His Phe Val Val 140 145 150 Asp Arg Lys Lys Val Thr Glu Val Ile Lys Cys Arg Asn Glu Ile 155 160 165 Met His Ser Ser Glu Met Lys Val Ser Ser Thr Trp Leu Arg Asp 170 175 180 Phe Gln Met Lys Ile Gln Asn Phe Leu Asn Glu Phe Lys Asn Ile 185 190 195 Pro Glu Ile Val Ala Val Tyr Ser Arg Ile Glu Gln Leu Leu Thr 200 205 210 Ser Asp Trp Ala Val His Ile Pro Glu Glu Asp Gln Arg Asp Gly 215 220 225 Cys Glu Cys Glu Met Gly Thr Tyr Leu Ser Glu Ser Gln Val Asn 230 235 240 Glu Ile Glu Met Gln Leu Leu Lys Glu Lys Leu Gln Glu Ile Tyr 245 250 255 Leu Gln Ala Glu Glu Gln Glu Val Leu Pro Glu Glu Leu Ser Asn 260 265 270 Arg Leu Glu Val Val Lys Glu Phe Leu Arg Asn Asn Glu Asp Leu 275 280 285 Arg Asn Gly Leu Thr Glu Asp Met Gln Lys Leu Asp Ser Leu Cys 290 295 300 Leu His Gln Lys Leu Asp Ser Gln Glu Pro Gly Arg Gln Thr Pro 305 310 315 Asp Arg Lys Ala <210> 2 <211> 57 <212> PRT <213> Homo sapiens <400> 2 Met Ser Cys Leu Met Val Glu Arg Cys Gly Glu Ile Leu Phe Glu 5 10 15 Asn Pro Asp Gln Asn Ala Lys Cys Val Cys Met Leu Gly Asp Ile 20 25 30 Arg Leu Arg Gly Gln Thr Gly Val Arg Ala Glu Arg Arg Gly Ser 35 40 45 Tyr Pro Phe Ile Asp Phe Arg Leu Leu Asn Ser Glu 50 55 <210> 3 <211> 62 <212> PRT <213> Homo sapiens <400> 3 Met Ile Arg Ser Lys Phe Arg Val Pro Arg Ile Leu His Val Leu 5 10 15 Ser Ala His Ser Gln Ala Ser Asp Lys Asn Phe Thr Ala Glu Asn 20 25 30 Ser Glu Val Val Val Ser Ser Arg Thr Asp Val Ser Pro Met Lys 35 40 45 Ser Asp Leu Leu Leu Pro Pro Ser Lys Pro Gly Cys Asn Asn Val 50 55 60 Leu Asn <210> 4 <211> 146 <212> PRT <213> Homo sapiens <400> 4 Met Val Gln Gly Met Cys Ser Pro Ser Pro Phe Gly Thr Ser Arg 5 10 15 Ala Cys Thr Val Gly Thr Gln Val Asp Ser Arg Ser Leu Pro Trp 20 25 30 Ala Leu Gly Ala Ser Ala Gln Arg Gly Asn Ile Pro Thr Ala Thr 35 40 45 Cys Ala Arg Thr Ala Gly Thr Leu Arg Arg Gly Leu Gln Pro Gly 50 55 60 Trp Gly Trp Glu Asp Phe Leu Asp Glu Gly Gln Pro Gly Phe Ser 65 70 75 Ser Arg Met Ser Trp Ser Arg Pro Pro Ala Gln Glu Gln Gly Ala 80 85 90 Gly Arg Gly Pro Ser Trp Val Arg Gly Leu Gly Gln Pro Thr Ala 95 100 105 Ala Phe Glu Gln Gly Pro Arg Ser Ser Val Ser Pro Gln Trp Glu 110 115 120 Gly Gly Gly Gln Gly Pro Gly Glu Leu Gly Arg Lys His Leu Leu 125 130 135 Gly Pro Ser Gln His His Pro Thr Asp Arg His 140 145 <210> 5 <211> 1039 <212> PRT <213> Homo sapiens <400> 5 Met Ala Val Gln Leu Val Pro Asp Ser Ala Leu Gly Leu Leu Met 5 10 15 Met Thr Glu Gly Arg Arg Cys Gln Val His Leu Leu Asp Asp Arg 20 25 30 Lys Leu Glu Leu Leu Val Gln Pro Lys Leu Leu Ala Lys Glu Leu 35 40 45 Leu Asp Leu Val Ala Ser His Phe Asn Leu Glu Lys Glu Tyr 50 55 60 Phe Gly Ile Ala Phe Thr Asp Glu Thr Gly His Leu Asn Trp Leu 65 70 75 Gln Leu Asp Arg Arg Val Leu Glu His Asp Phe Pro Lys Lys Ser 80 85 90 Gly Pro Val Val Leu Tyr Phe Cys Val Arg Phe Tyr Ile Glu Ser 95 100 105 Ile Ser Tyr Leu Lys Asp Asn Ala Thr Ile Glu Leu Phe Phe Leu 110 115 120 Asn Only Lys Ser Cys Ile Tyr Lys Glu Leu Ile Asp Val Asp Ser 125 130 135 Glu Val Val Phe Glu Leu Ala Ser Tyr Ile Leu Gln Glu Ala Lys 140 145 150 Gly Asp Phe Ser Asn Glu Val Val Arg Ser Asp Leu Lys Lys 155 160 165 Leu Pro Ala Leu Pro Thr Gln Ala Leu Lys Glu His Pro Ser Leu 170 175 180 Only Tyr Cys Glu Asp Arg Val Ile Glu His Tyr Lys Lys Leu Asn 185 190 195 Gly Gln Thr Arg Gly Gln Ala Ile Val Asn Tyr Met Ser Ile Val 200 205 210 Glu Ser Leu Pro Thr Tyr Gly Val His Tyr Tyr Ala Val Lys Asp 215 220 225 Lys Gln Gly Ile Pro Trp Trp Leu Gly Leu Ser Tyr Lys Gly Ile 230 235 240 Phe Gln Tyr Asp Tyr His Asp Lys Val Lys Pro Arg Lys Ile Phe 245 250 255 Gln Trp Arg Gln Leu Glu Asn Leu Tyr Phe Arg Glu Lys Lys Phe 260 265 270 Ser Val Glu Val His Asp Pro Arg Arg Ala Ser Val Thr Arg Arg 275 280 285 Thr Phe Gly His Ser Gly Ile Ala Val His Thr Trp Tyr Ala Cys 290 295 300 Pro Ala Leu Ile Lys Ser Ile Trp Ala Met Ala Ile Ser Gln His 305 310 315 Gln Phe Tyr Leu Asp Arg Lys Gln Ser Lys Ser Lys Ile His Ala 320 325 330 Ala Arg Ser Leu Ser Glu Ile Ala Ile Asp Leu Thr Glu Thr Gly 335 340 345 Thr Leu Lys Thr Ser Lys Leu Ala Asn Met Gly Ser Lys Gly Lys 350 355 360 Ile Ile Ser Gly Ser Ser Gly Ser Leu Leu Ser Ser Gly Ser Gln 365 370 375 Glu Ser Asp Ser Ser Gln Ser Ala Lys Lys Asp Met Leu Ala Ala 380 385 390 Leu Lys Ser Arg Gln Glu Ala Leu Glu Glu Thr Leu Arg Gln Arg 395 400 405 Leu Glu Glu Leu Lys Lys Leu Cys Leu Arg Glu Ala Glu Leu Thr 410 415 420 Gly Lys Leu Pro Val Glu Tyr Pro Leu Asp Pro Gly Glu Glu Pro 425 430 435 Pro Ile Val Arg Arg Arg Ile Gly Thr Ala Phe Lys Leu Asp Glu 440 445 450 Gln Lys Ile Leu Pro Lys Gly Glu Glu Ala Glu Leu Glu Arg Leu 455 460 465 Glu Arg Glu Phe Ala Ile Gln Ser Gln Ile Thr Glu Ala Ala Arg 470 475 480 Arg Leu Ala Ser Asp Pro Asn Val Ser Lys Lys Leu Lys Lys Gln 485 490 495 Arg Lys Thr Ser Tyr Leu Asn Ala Leu Lys Lys Leu Gln Glu Ile 500 505 510 Glu Asn Ala Ile Asn Glu Asn Arg Ile Lys Ser Gly Lys Lys Pro 515 520 525 Thr Gln Arg Ala Ser Leu Ile Ile Asp Asp Gly Asn Ile Ala Ser 530 535 540 Glu Asp Ser Ser Leu Ser Asp Ala Leu Val Leu Glu Asp Glu Asp 545 550 555 Ser Gln Val Thr Ser Thr Ile Ser Pro Leu His Ser Pro His Lys 560 565 570 Gly Leu Pro Pro Arg Pro Pro Ser His Asn Arg Pro Pro Pro Pro 575 580 585 Gln Ser Leu Glu Gly Leu Arg Gln Met His Tyr His Arg Asn Asp 590 595 600 Tyr Asp Lys Ser Pro Ile Lys Pro Lys Met Trp Ser Glu Ser Ser 605 610 615 Leu Asp Glu Pro Tyr Glu Lys Val Lys Lys Arg Ser Ser His Ser 620 625 630 His Ser Ser Ser His Lys Arg Phe Pro Ser Thr Gly Ser Cys Ala 635 640 645 Glu Ala Gly Gly Gly Ser Asn Ser Leu Gln Asn Ser Pro Ile Arg 650 655 660 Gly Leu Pro His Trp Asn Ser Gln Ser Ser Met Pro Ser Thr Pro 665 670 675 Asp Leu Arg Val Arg Ser Pro His Tyr Val His Ser Thr Arg Ser 680 685 690 Val Asp Ile Ser Pro Thr Arg Leu His Ser Leu Ala Leu His Phe 695 700 705 Arg His Arg Ser Ser Ser Leu Glu Ser Gln Gly Lys Leu Leu Gly 710 715 720 Ser Glu Asn Asp Thr Gly Ser Pro Asp Phe Tyr Thr Pro Arg Thr 725 730 735 Arg Ser Ser Asn Gly Ser Asp Pro Met Asp Asp Cys Ser Ser Cys 740 745 750 Thr Ser His Ser Ser Ser Glu His Tyr Tyr Pro Ala Gln Met Asn 755 760 765 Ala Asn Tyr Ser Thr Leu Ala Glu Asp Ser Pro Ser Lys Ala Arg 770 775 780 Gln Arg Gln Arg Gln Arg Gln Arg Ala Ala Gly Ala Leu Gly Ser 785 790 795 Ala Ser Ser Gly Ser Met Pro Asn Leu Ala Ala Arg Gly Gly Ala 800 805 810 Gly Gly Ala Gly Gly Ala Gly Gly Gly Val Tyr Leu His Ser Gln 815 820 825 Ser Gln Pro Ser Ser Gln Tyr Arg Ile Lys Glu Tyr Pro Leu Tyr 830 835 840 Ile Glu Gly Gly Ala Thr Pro Val Val Val Arg Ser Leu Glu Ser 845 850 855 Asp Gln Glu Gly His Tyr Ser Val Lys Ala Gln Phe Lys Thr Ser 860 865 870 Asn Ser Tyr Thr Ala Gly Gly Leu Phe Lys Glu Ser Trp Arg Gly 875 880 885 Gly Gly Gly Asp Glu Gly Asp Thr Gly Arg Leu Thr Pro Ser Arg 890 895 900 Ser Gln Ile Leu Arg Thr Pro Ser Leu Gly Arg Glu Gly Ala His 905 910 915 Asp Lys Gly Ala Gly Arg Ala Ala Val Ser Asp Glu Leu Arg Gln 920 925 930 Trp Tyr Gln Arg Ser Thr Ala Ser His Lys Glu His Ser Arg Leu 935 940 945 Ser His Thr Ser Ser Thr Ser Ser Asp Ser Gly Ser Gln Tyr Ser 950 955 960 Thr Ser Ser Gln Ser Thr Phe Val Ala His Ser Arg Val Thr Arg 965 970 975 Met Pro Gln Met Cys Lys Ala Thr Ser Ala Ala Leu Pro Gln Ser 980 985 990 Gln Arg Ser Ser Thr Pro Ser Ser Glu Ile Gly Ala Thr Pro Pro 995 1000 1005 Ser Ser Pro His His Ile Leu Thr Trp Gln Thr Gly Glu Ala Thr 1010 1015 1020 Glu Asn Ser Pro Ile Leu Asp Gly Ser Glu Ser Pro Pro His Gln 1025 1030 1035 Ser Thr Asp Glu <210> 6 <211> 244 <212> PRT <213> Homo sapiens <400> 6 Met Ala Ala Ala Ala Ser Pro Ala Ile Leu Pro Arg Leu Ala Ile 5 10 15 Leu Pro Tyr Leu Leu Phe Asp Trp Ser Gly Thr Gly Arg Ala Asp 20 25 30 Ala His Ser Leu Trp Tyr Asn Phe Thr Ile Ile His Leu Pro Arg 35 40 45 His Gly Gln Gln Trp Cys Glu Val Gln Ser Gln Val Asp Gln Lys 50 55 60 Asn Phe Leu Ser Tyr Asp Cys Gly Ser Asp Lys Val Leu Ser Met 65 70 75 Gly His Leu Glu Glu Gln Leu Tyr Ala Thr Asp Ala Trp Gly Lys 80 85 90 Gln Leu Glu Met Leu Arg Glu Val Gly Gln Arg Leu Arg Leu Glu 95 100 105 Leu Ala Asp Thr Glu Leu Glu Asp Phe Thr Pro Ser Gly Pro Leu 110 115 120 Thr Leu Gln Val Arg Met Ser Cys Glu Cys Glu Ala Asp Gly Tyr 125 130 135 Ile Arg Gly Ser Trp Gln Phe Ser Phe Asp Gly Arg Lys Phe Leu 140 145 150 Leu Phe Asp Ser Asn Asn Arg Lys Trp Thr Val Val His Ala Gly 155 160 165 Ala Arg Arg Met Lys Glu Lys Trp Glu Lys Asp Ser Gly Leu Thr 170 175 180 Thr Phe Phe Lys Met Val Ser Met Arg Asp Cys Lys Ser Trp Leu 185 190 195 Arg Asp Phe Leu Met His Arg Lys Lys Arg Leu Glu Pro Thr Ala 200 205 210 Pro Pro Thr Met Ala Pro Gly Leu Ala Gln Pro Lys Ala Ile Ala 215 220 225 Thr Thr Leu Ser Pro Trp Ser Phe Leu Ile Ile Leu Cys Phe Ile 230 235 240 Leu Pro Gly Ile <210> 7 <211> 536 <212> PRT <213> Homo sapiens <400> 7 Met Glu Ile Arg Gln His Glu Trp Leu Ser Ala Ser Pro His Glu 5 10 15 Gly Phe Glu Gln Met Arg Leu Lys Ser Arg Pro Lys Glu Pro Ser 20 25 30 Pro Ser Leu Thr Arg Val Gly Ala Asn Phe Tyr Ser Ser Val Lys 35 40 45 Gln Gln Asp Tyr Ser Ala Ser Val Trp Leu Arg Arg Lys Asp Lys 50 55 60 Leu Glu His Ser Gln Gln Lys Cys Ile Val Ile Phe Ala Leu Val 65 70 75 Cys Cys Phe Ala Ile Leu Val Ala Leu Ile Phe Ser Ala Val Asp 80 85 90 Ile Met Gly Glu Asp Glu Asp Gly Leu Ser Glu Lys Asn Cys Gln 95 100 105 Asn Lys Cys Arg Ile Ala Leu Val Glu Asn Ile Pro Glu Gly Leu 110 115 120 Asn Tyr Ser Glu Asn Ala Pro Phe His Leu Ser Leu Phe Gln Gly 125 130 135 Trp Met Asn Leu Leu Asn Met Ala Lys Lys Ser Val Asp Ile Val 140 145 150 Ser Ser His Trp Asp Leu Asn His Thr His Pro Ser Ala Cys Gln 155 160 165 Gly Gln Arg Leu Phe Glu Lys Leu Leu Gln Leu Thr Ser Gln Asn 170 175 180 Ile Glu Ile Lys Leu Val Ser Asp Val Thr Ala Asp Ser Lys Val 185 190 195 Leu Glu Ala Leu Lys Leu Lys Gly Ala Glu Val Thr Tyr Met Asn 200 205 210 Met Thr Ala Tyr Asn Lys Gly Arg Leu Gln Ser Ser Phe Trp Ile 215 220 225 Val Asp Lys Gln His Val Tyr Ile Gly Ser Ala Gly Leu Asp Trp 230 235 240 Gln Ser Leu Gly Gln Met Lys Glu Leu Gly Val Ile Phe Tyr Asn 245 250 255 Cys Ser Cys Leu Val Leu Asp Leu Gln Arg Ile Phe Ala Leu Tyr 260 265 270 Ser Ser Leu Lys Phe Lys Ser Arg Val Pro Gln Thr Trp Ser Lys 275 280 285 Arg Leu Tyr Gly Val Tyr Asp Asn Glu Lys Lys Leu Gln Leu Gln 290 295 300 Leu Asn Glu Thr Lys Ser Gln Ala Phe Val Ser Asn Ser Pro Lys 305 310 315 Leu Phe Cys Pro Lys Asn Arg Ser Phe Asp Ile Asp Ala Ile Tyr 320 325 330 Ser Val Ile Asp Asp Ala Lys Gln Tyr Val Tyr Ile Ala Val Met 335 340 345 Asp Tyr Leu Pro Ile Ser Ser Thr Ser Thr Lys Arg Thr Tyr Trp 350 355 360 Pro Asp Leu Asp Ala Lys Ile Arg Glu Ala Leu Val Leu Arg Ser 365 370 375 Val Arg Val Arg Leu Leu Leu Ser Phe Trp Lys Glu Thr Asp Pro 380 385 390 Leu Thr Phe Asn Phe Ile Ser Ser Leu Lys Ala Ile Cys Thr Glu 395 400 405 Ile Ala Asn Cys Ser Leu Lys Val Lys Phe Phe Asp Leu Glu Arg 410 415 420 Glu Asn Ala Cys Ala Thr Lys Glu Gln Lys Asn His Thr Phe Pro 425 430 435 Arg Leu Asn Arg Asn Lys Tyr Met Val Thr Asp Gly Ala Ala Tyr 440 445 450 Ile Gly Asn Phe Asp Trp Val Gly Asn Asp Phe Thr Gln Asn Ala 455 460 465 Gly Thr Gly Leu Val Ile Asn Gln Ala Asp Val Arg Asn Asn Arg 470 475 480 Ser Ile Ile Lys Gln Leu Lys Asp Val Phe Glu Arg Asp Trp Tyr 485 490 495 Ser Pro Tyr Ala Lys Thr Leu Gln Pro Thr Lys Gln Pro Asn Cys 500 505 510 Ser Ser Leu Phe Lys Leu Lys Pro Leu Ser Asn Lys Thr Ala Thr 515 520 525 Asp Asp Thr Gly Gly Lys Asp Pro Arg Asn Val 530 535 <210> 8 <211> 344 <212> PRT <213> Homo sapiens <400> 8 Gln Asn Leu Pro Ser Ser Pro Ala Pro Ser Thr Ile Phe Ser Gly 5 10 15 Gly Phe Arg His Gly Ser Leu Ile Ser Ile Asp Ser Thr Cys Thr 20 25 30 Glu Met Gly Asn Phe Asp Asn Ala Asn Val Thr Gly Glu Ile Glu 35 40 45 Phe Ala Ile His Tyr Cys Phe Lys Thr His Ser Leu Glu Ile Cys 50 55 60 Ile Lys Ala Cys Lys Asn Leu Ala Tyr Gly Glu Glu Lys Lys Lys 65 70 75 Lys Cys Asn Pro Tyr Val Lys Thr Tyr Leu Leu Pro Asp Arg Ser 80 85 90 Ser Gln Gly Lys Arg Lys Thr Gly Val Gln Arg Asn Thr Val Asp 95 100 105 Pro Thr Phe Gln Glu Thr Leu Lys Tyr Gln Val Ala Pro Ala Gln 110 115 120 Leu Val Thr Arg Gln Leu Gln Val Ser Val Trp His Leu Gly Thr 125 130 135 Leu Ala Arg Arg Val Phe Leu Gly Glu Val Ile Ile Ser Leu Ala 140 145 150 Thr Trp Asp Phe Glu Asp Ser Thr Thr Gln Ser Phe Arg Trp His 155 160 165 Pro Leu Arg Ala Lys Ala Glu Lys Tyr Glu Asp Ser Val Pro Gln 170 175 180 Ser Asn Gly Glu Leu Thr Val Arg Ala Lys Leu Val Leu Pro Ser 185 190 195 Arg Pro Arg Lys Leu Gln Glu Ala Gln Glu Gly Thr Asp Gln Pro 200 205 210 Ser Leu His Gly Gln Leu Cys Leu Val Val Leu Gly Ala Lys Asn 215 220 225 Leu Pro Val Arg Pro Asp Gly Thr Leu Asn Ser Phe Val Lys Gly 230 235 240 Cys Leu Thr Leu Pro Asp Gln Gln Lys Leu Arg Leu Lys Ser Pro 245 250 255 Val Leu Arg Lys Gln Ala Cys Pro Gln Trp Lys His Ser Phe Val 260 265 270 Phe Ser Gly Val Thr Pro Ala Gln Leu Arg Gln Ser Ser Leu Glu 275 280 285 Leu Thr Val Trp Asp Gln Ala Leu Phe Gly Met Asn Asp Arg Leu 290 295 300 Leu Gly Gly Thr Arg Leu Gly Ser Lys Gly Asp Thr Ala Val Gly 305 310 315 Gly Asp Ala Cys Ser Leu Ser Lys Leu Gln Trp Gln Lys Val Leu 320 325 330 Ser Ser Pro Asn Leu Trp Thr Asp Met Thr Leu Val Leu His <210> 9 <211> 263 <212> PRT <213> Homo sapiens <400> 9 Met Phe Arg Asn Gln Tyr Asp Asn Asp Val Thr Val Trp Ser Pro 5 10 15 Gln Gly Arg Ile His Gln Ile Glu Tyr Ala Met Glu Ala Val Lys 20 25 30 Gln Gly Ser Ala Thr Val Gly Leu Lys Ser Lys Thr His Ala Val 35 40 45 Leu Val Ala Leu Lys Arg Ala Gln Ser Glu Leu Ala Ala His Gln 50 55 60 Lys Lys Ile Leu His Val Asp Asn His Ile Gly Ile Ser Ile Ala 65 70 75 Gly Leu Thr Ala Asp Ala Arg Leu Leu Cys Asn Phe Met Arg Gln 80 85 90 Glu Cys Leu Asp Ser Arg Phe Val Phe Asp Arg Pro Leu Pro Val 95 100 105 Ser Arg Leu Val Ser Leu Ile Gly Ser Lys Thr Gln Ile Pro Thr 110 115 120 Gln Arg Tyr Gly Arg Arg Pro Tyr Gly Val Gly Leu Leu Ile Ala 125 130 135 Gly Tyr Asp Asp Met Gly Pro His Ile Phe Gln Thr Cys Pro Ser 140 145 150 Ala Asn Tyr Phe Asp Cys Arg Ala Met Ser Ile Gly Ala Arg Ser 155 160 165 Gln Ser Ala Arg Thr Tyr Leu Glu Arg His Met Ser Glu Phe Met 170 175 180 Glu Cys Asn Leu Asn Glu Leu Val Lys His Gly Leu Arg Ala Leu 185 190 195 Arg Glu Thr Leu Pro Ala Glu Gln Asp Leu Thr Thr Lys Asn Val 200 205 210 Ser Ile Gly Ile Val Gly Lys Asp Leu Glu Phe Thr Ile Tyr Asp 215 220 225 Asp Asp Asp Val Ser Pro Phe Leu Glu Gly Leu Glu Glu Arg Pro 230 235 240 Gln Arg Lys Ala Gln Pro Ala Gln Pro Ala Asp Glu Pro Ala Glu 245 250 255 Lys Ala Asp Glu Pro Met Glu His 260 <210> 10 <211> 287 <212> PRT <213> Homo sapiens <400> 10 Met Lys Asp Arg Leu Ala Glu Leu Leu Asp Leu Ser Lys Gln Tyr 5 10 15 Asp Gln Gln Phe Pro Asp Gly Asp Asp Glu Phe Asp Ser Pro His 20 25 30 Glu Asp Ile Val Phe Glu Thr Asp His Ile Leu Glu Ser Leu Tyr 35 40 45 Arg Asp Ile Arg Asp Ile Gln Asp Glu Asn Gln Leu Leu Val Ala 50 55 60 Asp Val Lys Arg Leu Gly Lys Gln Asn Ala Arg Phe Leu Thr Ser 65 70 75 Met Arg Arg Leu Ser Ser Ile Lys Arg Asp Thr Asn Ser Ile Ala 80 85 90 Lys Ala Ile Lys Ala Arg Gly Glu Val Ile His Cys Lys Leu Arg 95 100 105 Ala Met Lys Glu Leu Ser Glu Ala Ala Glu Ala Gln His Gly Pro 110 115 120 His Ser Ala Val Ala Arg Ile Ser Arg Ala Gln Tyr Asn Ala Leu 125 130 135 Thr Leu Thr Phe Gln Arg Ala Met His Asp Tyr Asn Gln Ala Glu 140 145 150 Met Lys Gln Arg Asp Asn Cys Lys Ile Arg Ile Gln Arg Gln Leu 155 160 165 Glu Ile Met Gly Lys Glu Val Ser Gly Asp Gln Ile Glu Asp Met 170 175 180 Phe Glu Gln Gly Lys Trp Asp Val Phe Ser Glu Asn Leu Leu Ala 185 190 195 Asp Val Lys Gly Ala Arg Ala Ala Leu Asn Glu Ile Glu Ser Arg 200 205 210 His Arg Glu Leu Leu Arg Leu Glu Ser Arg Ile Arg Asp Val His 215 220 225 Glu Leu Phe Leu Gln Met Ala Val Leu Val Glu Lys Gln Ala Asp 230 235 240 Thr Leu Asn Val Ile Glu Leu Asn Val Gln Lys Thr Val Asp Tyr 245 250 255 Thr Gly Gln Ala Lys Ala Gln Val Arg Lys Ala Val Gln Tyr Glu 260 265 270 Glu Lys Asn Pro Cys Arg Thr Leu Cys Cys Phe Cys Cys Pro Cys 275 280 285 Leu Lys <210> 11 <211> 244 <212> PRT <213> Homo sapiens <400> 11 Met Ala Ala Ala Ala Ser Pro Ala Ile Leu Pro Arg Leu Ala Ile 5 10 15 Leu Pro Tyr Leu Leu Phe Asp Trp Ser Gly Thr Gly Arg Ala Asp 20 25 30 Ala His Ser Leu Trp Tyr Asn Phe Thr Ile Ile His Leu Pro Arg 35 40 45 His Gly Gln Gln Trp Cys Glu Val Gln Ser Gln Val Asp Gln Lys 50 55 60 Asn Phe Leu Ser Tyr Asp Cys Gly Ser Asp Lys Val Leu Ser Met 65 70 75 Gly His Leu Glu Glu Gln Leu Tyr Ala Thr Asp Ala Trp Gly Lys 80 85 90 Gln Leu Glu Met Leu Arg Glu Val Gly Gln Arg Leu Arg Leu Glu 95 100 105 Leu Ala Asp Thr Glu Leu Glu Asp Phe Thr Pro Ser Gly Pro Leu 110 115 120 Thr Leu Gln Val Arg Met Ser Cys Glu Cys Glu Ala Asp Gly Tyr 125 130 135 Ile Arg Gly Ser Trp Gln Phe Ser Phe Asp Gly Arg Lys Phe Leu 140 145 150 Leu Phe Asp Ser Asn Asn Arg Lys Trp Thr Val Val His Ala Gly 155 160 165 Ala Arg Arg Met Lys Glu Lys Trp Glu Lys Asp Ser Gly Leu Thr 170 175 180 Thr Phe Phe Lys Met Val Ser Met Arg Asp Cys Lys Ser Trp Leu 185 190 195 Arg Asp Phe Leu Met His Arg Lys Lys Arg Leu Glu Pro Thr Ala 200 205 210 Pro Pro Thr Met Ala Pro Gly Leu Ala Gln Pro Lys Ala Ile Ala 215 220 225 Thr Thr Leu Ser Pro Trp Ser Phe Leu Ile Ile Leu Cys Phe Ile 230 235 240 Leu Pro Gly Ile <210> 12 <211> 322 <212> PRT <213> Homo sapiens <400> 12 Met Ser Ala Lys Ser Arg Thr Ile Gly Ile Ile Gly Ala Pro Phe Ser 1 5 10 15 Lys Gly Gln Pro Arg Gly Gly Val Glu Glu Gly Pro Thr Val Leu Arg 20 25 30 Lys Ala Gly Leu Leu Glu Lys Leu Lys Glu Gln Glu Cys Asp Val Lys 35 40 45 Asp Tyr Gly Asp Leu Pro Phe Ala Asp Ile Pro Asn Asp Ser Pro Phe 50 55 60 Gln Ile Val Lys Asn Pro Arg Ser Val Gly Lys Ala Ser Glu Gln Leu 65 70 75 80 Ala Gly Lys Val Ala Glu Val Lys Lys Asn Gly Arg Ile Ser Leu Val 85 90 95 Leu Gly Gly Asp His Ser Leu Ala Ile Gly Ser Ile Ser Gly His Ala 100 105 110 Arg Val His Pro Asp Leu Gly Val Ile Trp Val Asp Ala His Thr Asp 115 120 125 Ile Asn Thr Pro Leu Thr Thr Thr Ser Gly Asn Leu His Gly Gln Pro 130 135 140 Val Ser Phe Leu Leu Lys Glu Leu Lys Gly Lys Ile Pro Asp Val Pro 145 150 155 160 Gly Phe Ser Trp Val Thr Pro Cys Ile Ser Ala Lys Asp Ile Val Tyr 165 170 175 Ile Gly Leu Arg Asp Val Asp Pro Gly Glu His Tyr Ile Leu Lys Thr 180 185 190 Leu Gly Ile Lys Tyr Phe Ser Met Thr Glu Val Asp Arg Leu Gly Ile 195 200 205 Gly Lys Val Met Glu Glu Thr Leu Ser Tyr Leu Leu Gly Arg Lys Lys 210 215 220 Arg Pro Ile His Leu Ser Phe Asp Val Asp Gly Leu Asp Pro Ser Phe 225 230 235 240 Thr Pro Ala Thr Gly Thr Pro Val Val Gly Gly Leu Thr Tyr Arg Glu 245 250 255 Gly Leu Tyr Ile Thr Glu Glu Ile Tyr Lys Thr Gly Leu Leu Ser Gly 260 265 270 Leu Asp Ile Met Glu Val Asn Pro Ser Leu Gly Lys Thr Pro Glu Glu 275 280 285 Val Thr Arg Thr Val Asn Thr Ala Val Ala Ile Thr Leu Ala Cys Phe 290 295 300 Gly Leu Ala Arg Glu Gly Asn His Lys Pro Ile Asp Tyr Leu Asn Pro 305 310 315 320 Pro Lys <210> 13 <211> 213 <212> PRT <213> Homo sapiens <400> 13 Met Asp Thr Glu Arg Val Gly Asp Gly Lys Gln His Arg Arg Lys Gln 1 5 10 15 Ser Gln Arg Leu Arg Trp Pro Cys Cys Leu Ala Leu Val Pro Asp Arg 20 25 30 His Pro Ser Gln Leu Ser Ser Cys Thr Leu Cys Leu Leu Ala Ala Ala 35 40 45 Ser Gln Trp Glu Ser Trp Ala His Phe Ser Lys Trp His Thr Glu Ala 50 55 60 Ser Thr Gly Thr His Leu Gly Lys Ala Lys Ala Glu Gly Leu Gly Cys 65 70 75 80 Thr Val Lys Asn Thr Pro Gln Leu Ser Ile Cys Glu Pro Ser His Phe 85 90 95 Gly Pro Ser Phe Val His Ser Pro His Leu Leu Val Asp His Asp His 100 105 110 Arg Ala Gly Ala Ala Thr Gly Arg Gly Gln Ala Gly Pro Ser Arg Ala 115 120 125 Ser Ser Val Ser Pro Thr Phe Cys Pro Pro Thr Thr Ser His His Pro 130 135 140 Val Cys Ala Lys Gly Thr Asp Pro Val Leu Val Leu Gln Glu Glu Glu 145 150 155 160 Gln Asp Leu Asp Gly Glu Lys Gly Pro Ser Ser Glu Gly Pro Glu Glu 165 170 175 Glu Asp Gly Glu Gly Phe Ser Phe Lys Tyr Ser Pro Gly Lys Leu Arg 180 185 190 Gly Asn Gln Tyr Lys Lys Met Met Thr Lys Glu Glu Leu Glu Glu Glu 195 200 205 Gln Arg Thr Glu Glu 210 <210> 14 <211> 117 <212> PRT <213> Homo sapiens <400> 14 Gly Glu Ala Arg Gly Lys Leu Leu Gln Leu Ile Glu Gln Gln Lys Leu 1 5 10 15 Val Gly Leu Asn Leu Ser Pro Pro Met Ser Pro Val Gln Leu Pro Leu 20 25 30 Arg Ala Trp Thr Glu Gly Ala Lys Arg Thr Ile Glu Val Ser Ile Pro 35 40 45 Gly Ala Glu Ala Pro Glu Ser Ser Lys Cys Ser Thr Val Ser Pro Val 50 55 60 Ser Gly Ile Asn Thr Arg Arg Ser Ser Gly Ala Thr Gly Asn Ser Cys 65 70 75 80 Ser Pro Leu Asn Ala Thr Ser Gly Ser Gly Arg Phe Thr Pro Leu Asn 85 90 95 Pro Arg Ala Lys Ile Glu Lys Gln Asn Glu Glu Gly Trp Phe Ala Leu 100 105 110 Ser Thr His Val Ser 115 <210> 15 <211> 1046 <212> PRT <213> Homo sapiens <400> 15 Arg Gln Gly Gly Arg Pro Ser Ser Pro Gln Ala Ser Arg Ala Arg Gln 1 5 10 15 Leu Pro Ser Ile Glu Ile Gln Gln Trp Glu Gln Asn Leu Glu Lys Phe 20 25 30 His Met Asp Leu Phe Arg Met Arg Cys Tyr Leu Ala Ser Leu Gln Gly 35 40 45 Gly Glu Leu Pro Asn Pro Lys Ser Leu Leu Ala Ala Ala Ser Arg Pro 50 55 60 Ser Lys Leu Ala Leu Gly Arg Leu Gly Ile Leu Ser Val Ser Ser Phe 65 70 75 80 His Ala Leu Val Cys Ser Arg Asp Asp Ser Ala Leu Arg Lys Arg Thr 85 90 95 Leu Ser Leu Thr Gln Arg Gly Arg Asn Lys Lys Gly Ile Phe Ser Ser 100 105 110 Leu Lys Gly Leu Asp Thr Leu Ala Arg Lys Gly Lys Glu Lys Arg Pro 115 120 125 Ser Ile Thr Gln Val Asp Glu Leu Leu His Ile Tyr Gly Ser Thr Val 130 135 140 Asp Gly Val Pro Arg Asp Asn Ala Trp Glu Ile Gln Thr Tyr Val His 145 150 155 160 Phe Gln Asp Asn His Gly Val Thr Val Gly Ile Lys Pro Glu His Arg 165 170 175 Val Glu Asp Ile Leu Thr Leu Ala Cys Lys Met Arg Gln Leu Glu Pro 180 185 190 Ser His Tyr Gly Leu Gln Leu Arg Lys Leu Val Asp Asp Asn Val Glu 195 200 205 Tyr Cys Ile Pro Ala Pro Tyr Glu Tyr Met Gln Gln Gln Val Tyr Asp 210 215 220 Glu Ile Glu Val Phe Pro Leu Asn Val Tyr Asp Val Gln Leu Thr Lys 225 230 235 240 Thr Gly Ser Val Cys Asp Phe Gly Phe Ala Val Thr Ala Gln Val Asp 245 250 255 Glu Arg Gln His Leu Ser Arg Ile Phe Ile Ser Asp Val Leu Pro Asp 260 265 270 Gly Leu Ala Tyr Gly Glu Gly Leu Arg Lys Gly Asn Glu Ile Met Thr 275 280 285 Leu Asn Gly Glu Ala Val Ser Asp Leu Asp Leu Lys Gln Met Glu Ala 290 295 300 Leu Phe Ser Glu Lys Ser Val Gly Leu Thr Leu Ile Ala Arg Pro Pro 305 310 315 320 Asp Thr Lys Ala Thr Leu Cys Thr Ser Trp Ser Asp Ser Asp Leu Phe 325 330 335 Ser Arg Asp Gln Lys Ser Leu Leu Pro Pro Pro Asn Gln Ser Gln Leu 340 345 350 Leu Glu Glu Phe Leu Asp Asn Phe Lys Lys Asn Thr Ala Asn Asp Phe 355 360 365 Ser Asn Val Pro Asp Ile Thr Thr Gly Leu Lys Arg Ser Gln Thr Asp 370 375 380 Gly Thr Leu Asp Gln Val Ser His Arg Glu Lys Met Glu Gln Thr Phe 385 390 395 400 Arg Ser Ala Glu Gln Ile Thr Ala Leu Cys Arg Ser Phe Asn Asp Ser 405 410 415 Gln Ala Asn Gly Met Glu Gly Pro Arg Glu Asn Gln Asp Pro Pro Pro 420 425 430 Arg Ser Leu Ala Arg His Leu Ser Asp Ala Asp Arg Leu Arg Lys Val 435 440 445 Ile Gln Glu Leu Val Asp Thr Glu Lys Ser Tyr Val Lys Asp Leu Ser 450 455 460 Cys Leu Phe Glu Leu Tyr Leu Glu Pro Leu Gln Asn Glu Thr Phe Leu 465 470 475 480 Thr Gln Asp Glu Met Glu Ser Leu Phe Gly Ser Leu Pro Glu Met Leu 485 490 495 Glu Phe Gln Lys Val Phe Leu Glu Thr Leu Glu Asp Gly Ile Ser Ala 500 505 510 Ser Ser Asp Phe Asn Thr Leu Glu Thr Pro Ser Gln Phe Arg Lys Leu 515 520 525 Leu Phe Ser Leu Gly Gly Ser Phe Leu Tyr Tyr Ala Asp His Phe Lys 530 535 540 Leu Tyr Ser Gly Phe Cys Ala Asn His Ile Lys Val Gln Lys Val Leu 545 550 555 560 Glu Arg Ala Lys Thr Asp Lys Ala Phe Lys Ala Phe Leu Asp Ala Arg 565 570 575 Asn Pro Thr Lys Gln His Ser Ser Thr Leu Glu Ser Tyr Leu Ile Lys 580 585 590 Pro Val Gln Arg Val Leu Lys Tyr Pro Leu Leu Leu Lys Glu Leu Val 595 600 605 Ser Leu Thr Asp Gln Glu Ser Glu Glu His Tyr His Leu Thr Glu Ala 610 615 620 Leu Lys Ala Met Glu Lys Val Ala Ser His Ile Asn Glu Met Gln Lys 625 630 635 640 Ile Tyr Glu Asp Tyr Gly Thr Val Phe Asp Gln Leu Val Ala Glu Gln 645 650 655 Ser Gly Thr Glu Lys Glu Val Thr Glu Leu Ser Met Gly Glu Leu Leu 660 665 670 Met His Ser Thr Val Ser Trp Leu Asn Pro Phe Leu Ser Leu Gly Lys 675 680 685 Ala Arg Lys Asp Leu Glu Leu Thr Val Phe Val Phe Lys Arg Ala Val 690 695 700 Ile Leu Val Tyr Lys Glu Asn Cys Lys Leu Lys Lys Lys Leu Pro Ser 705 710 715 720 Asn Ser Arg Pro Ala His Asn Ser Thr Asp Leu Asp Pro Phe Lys Phe 725 730 735 Arg Trp Leu Ile Pro Ile Ser Ala Leu Gln Val Arg Leu Gly Asn Pro 740 745 750 Ala Gly Thr Glu Asn Asn Ser Ile Trp Glu Leu Ile His Thr Lys Ser 755 760 765 Glu Ile Glu Gly Arg Pro Glu Thr Ile Phe Gln Leu Cys Cys Ser Asp 770 775 780 Ser Glu Ser Lys Thr Asn Ile Val Lys Val Ile Arg Ser Ile Leu Arg 785 790 795 800 Glu Asn Phe Arg Arg His Ile Lys Cys Glu Leu Pro Leu Glu Lys Thr 805 810 815 Cys Lys Asp Arg Leu Val Pro Leu Lys Asn Arg Val Pro Val Ser Ala 820 825 830 Lys Leu Ala Ser Ser Arg Ser Leu Lys Val Leu Lys Asn Ser Ser Ser 835 840 845 Asn Glu Trp Thr Gly Glu Thr Gly Lys Gly Thr Leu Leu Asp Ser Asp 850 855 860 Glu Gly Ser Leu Ser Ser Gly Thr Gln Ser Ser Gly Cys Pro Thr Ala 865 870 875 880 Glu Gly Arg Gln Asp Ser Lys Ser Thr Ser Pro Gly Lys Tyr Pro His 885 890 895 Pro Gly Leu Ala Asp Phe Ala Asp Asn Leu Ile Lys Glu Ser Asp Ile 900 905 910 Leu Ser Asp Glu Asp Asp Asp His Arg Gln Thr Val Lys Gln Gly Ser 915 920 925 Pro Thr Lys Asp Ile Glu Ile Gln Phe Gln Arg Leu Arg Ile Ser Glu 930 935 940 Asp Pro Asp Val His Pro Glu Ala Glu Gln Gln Pro Gly Pro Glu Ser 945 950 955 960 Gly Glu Gly Gln Lys Gly Gly Glu Gln Pro Lys Leu Val Arg Gly His 965 970 975 Phe Cys Pro Ile Lys Arg Lys Ala Asn Ser Thr Lys Arg Asp Arg Gly 980 985 990 Thr Leu Leu Lys Ala Gln Ile Arg His Gln Ser Leu Asp Ser Gln Ser 995 1000 1005 Glu Asn Ala Thr Ile Asp Leu Asn Ser Val Leu Glu Arg Glu Phe 1010 1015 1020 Ser Val Gln Ser Leu Thr Ser Val Val Ser Glu Glu Cys Phe Tyr 1025 1030 1035 Glu Thr Glu Ser His Gly Lys Ser 1040 1045 <210> 16 <211> 232 <212> PRT <213> Homo sapiens <400> 16 Met Glu Asp Leu Glu Glu Asp Val Arg Phe Ile Val Asp Glu Thr Leu 1 5 10 15 Asp Phe Gly Gly Leu Ser Pro Ser Asp Ser Arg Glu Glu Glu Asp Ile 20 25 30 Thr Val Leu Val Thr Pro Glu Lys Pro Leu Arg Arg Gly Leu Ser His 35 40 45 Arg Ser Asp Pro Asn Ala Val Ala Pro Ala Pro Gln Gly Val Arg Leu 50 55 60 Ser Leu Gly Pro Leu Ser Pro Glu Lys Leu Glu Glu Ile Leu Asp Glu 65 70 75 80 Ala Asn Arg Leu Ala Ala Gln Leu Glu Gln Cys Ala Leu Gln Asp Arg 85 90 95 Glu Ser Ala Gly Glu Gly Leu Gly Pro Arg Arg Val Lys Pro Ser Pro 100 105 110 Arg Arg Glu Thr Phe Val Leu Lys Asp Ser Pro Val Arg Asp Leu Leu 115 120 125 Pro Thr Val Asn Ser Leu Thr Arg Ser Thr Pro Ser Pro Ser Ser Leu 130 135 140 Thr Pro Arg Leu Arg Ser Asn Asp Arg Lys Gly Ser Val Arg Ala Leu 145 150 155 160 Arg Ala Thr Ser Gly Lys Arg Pro Ser Asn Met Lys Arg Glu Ser Pro 165 170 175 Thr Cys Asn Leu Phe Pro Ala Ser Lys Ser Pro Ala Ser Ser Pro Leu 180 185 190 Thr Arg Ser Thr Pro Pro Val Arg Gly Arg Ala Gly Pro Ser Gly Arg 195 200 205 Ala Ala Ala Ser Pro Pro Thr Pro Ile Arg Ser Val Leu Ala Pro Gln 210 215 220 Pro Ser Thr Ser Asn Ser Gln Arg 225 230 <210> 17 <211> 63 <212> PRT <213> Homo sapiens <400> 17 Met Leu Gly Gln Ser Ile Arg Arg Phe Thr Thr Ser Val Val Arg Arg 1 5 10 15 Ser His Tyr Glu Glu Gly Pro Gly Lys Asn Leu Pro Phe Ser Val Glu 20 25 30 Asn Lys Trp Ser Leu Leu Ala Lys Met Cys Leu Tyr Phe Gly Ser Ala 35 40 45 Phe Ala Thr Pro Phe Leu Val Val Arg His Gln Leu Leu Lys Thr 50 55 60

Claims

1. A tool for determining whether the level of at least one group of biomarkers in a subject's blood sample is abnormal for the manufacture of a product for physiological characterization of a subject, wherein the biomarker group comprises the following biomarkers: interleukin (IL)-2, IL-5, IL-8, IL-10, MIF, matrix metalloproteinase 7 (MMP-7), MMP-9, resistin, SAA and myeloperoxidase (MPO), wherein abnormal levels of the biomarkers indicate non-small cell lung cancer.

2. The use according to claim 1, wherein the subject is a male.

3. The use according to claim 1, wherein the subject is a female.

4. The use according to claim 1, wherein Determining the level of a biomarker involves performing a quantitative multiplex immunoassay.

5. The use according to claim 1, wherein The blood sample is serum or plasma. The use according to claim 1 , wherein the subject is a mammal.

7. The use according to claim 1, wherein the biomarker panel consists of no more than 20 biomarkers.

8. The use according to claim 1, wherein the biomarker panel consists of no more than 10 biomarkers.